tranexamic acid and Pregnancy studies

Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.

Research Excerpts

Excerpt	Relevance	Reference
"This study aims to illustrate the impact of applying the tranexamic acid impregnated in a gelatin sponge between the anterior rectus sheath and the Rectus Abdominis muscle during Cesarean section (CS) in minimizing rectus sheath hematoma (RHS) in women treated with Warfarin."	9.69	Role of tranexamic acid-soaked gelatin sponge in minimizing rectus sheath hematoma after cesarean section in women treated with warfarin, a simple tool for high-risk cases, a randomized controlled trial. ( Hany, A; Mansour, A; Nabil, M; Sediek, M, 2023)
"Although prophylactic tranexamic acid administration after cesarean delivery resulted in a lower incidence of calculated estimated blood loss of >1000 mL or red cell transfusion by day 2, its failure to reduce the incidence of hemorrhage-related secondary clinical outcomes (TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery trial) makes its use questionable."	9.51	Tranexamic acid for the prevention of blood loss after cesarean among women with twins: a secondary analysis of the TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery randomized clinical trial. ( Azria, E; Benard, A; Bohec, C; Bouchghoul, H; Bretelle, F; Chauleur, C; Daniel, V; Darsonval, A; de Marcillac, F; Deneux-Tharaux, C; Desbrière, R; Froeliger, A; Fuchs, F; Gallot, D; Gauchotte, E; Georget, A; Haddad, B; Kayem, G; Korb, D; Le Lous, M; Le Ray, C; Legendre, G; Letouzey, V; Madar, H; Mattuizzi, A; Mottet, N; Parant, O; Perrotin, F; Regueme, S; Roussillon, C; Rozenberg, P; Salomon, LJ; Sananès, N; Sénat, MV; Sentilhes, L; Vardon, D; Verspyck, E; Winer, N, 2022)
"The evidence that early tranexamic acid treatment reduces postpartum hemorrhage deaths has major implications for obstetrical care worldwide."	9.41	Tranexamic acid for bleeding: Much more than a treatment for postpartum hemorrhage. ( Brenner, A; Roberts, I; Shakur-Still, H, 2023)
"To conduct the first-ever systematic review and meta-analysis of randomized controlled trials (RCTs) on the antihemorrhagic utility and safety of tranexamic acid (TXA) versus misoprostol for management (prevention and/or treatment) of postpartum hemorrhage (PPH)."	9.41	Tranexamic acid versus misoprostol for management of postpartum hemorrhage: A systematic review and meta-analysis of randomized controlled trials. ( Abdulmalik, NA; Abu-Zaid, A; Abuzaid, M; Albadawi, MI; Alblewi, H; Albouq, B; Alomar, O; Alsehaimi, SO; Alyousef, A; Baradwan, S; Bukhari, IA; Ghazi, A; Khadawardi, K; Salem, H, 2023)
"An antifibrinolytic agent that blocks lysine-binding sites on plasminogen molecules, tranexamic acid reduces bleeding-related mortality in women with postpartum hemorrhage (PPH), especially administered fairly soon after delivery."	9.34	TRAAP2 - TRAnexamic Acid for Preventing postpartum hemorrhage after cesarean delivery: a multicenter randomized, doubleblind, placebo- controlled trial - a study protocol. ( Daniel, V; Deneux-Tharaux, C; Sentilhes, L, 2020)
" This trial assessed the efficacy, safety, and acceptability of oral TXA when used as an adjunct to sublingual misoprostol to treat postpartum hemorrhage (PPH) following vaginal delivery."	9.34	A double-blind, randomized controlled trial to explore oral tranexamic acid as adjunct for the treatment for postpartum hemorrhage. ( Abbas, D; Diop, A; Martin, R; Ngoc, NTN; Razafi, A; Tuyet, HTD; Winikoff, B, 2020)
"To investigate the effect of adjunctive intravenous tranexamic acid (TA) on blood loss during cesarean section (CS) in patients with placenta previa undergone bilateral uterine arteryligation (BUAL)."	9.30	Bilateral uterine artery ligation plus intravenous tranexamic acid during cesarean delivery for placenta previa: a randomized double-blind controlled trial. ( Abbas, AM; Sallam, HF; Shady, NW, 2019)
"This study was designed to compare the effect of intravenous tranexamic acid (TXA) and prostaglandin analogue on reducing PPH resulted from uterine atony in women undergoing C section or vaginal delivery."	9.27	The Effect of Tranexamic Acid on Preventing Post-partum Hemorrhage Due to Uterine Atony: A Triple-blind Randomized Clinical Trial. ( Ahmadi, M; Nikbakht, R; Zargar, M, 2018)
"Tranexamic acid (TXA) effectively reduces bleeding in women with postpartum hemorrhage (PPH) in hospital settings."	9.22	Tranexamic Acid for Postpartum Hemorrhage Treatment in Low-Resource Settings: A Rapid Scoping Review. ( Bar-Zeev, S; Schulte-Hillen, C; Tran, NT; Zeck, W, 2022)
"To assess whether a policy of routine administration of high-dose tranexamic acid (TA) at the diagnosis of postpartum hemorrhage (PPH) reduces blood loss after vaginal birth."	9.22	Policy of high-dose tranexamic acid for treating postpartum hemorrhage after vaginal delivery. ( Bouet, PE; Descamps, P; Gillard, P; Legendre, G; Ruiz, V; Sentilhes, L, 2016)
"To assess the effects of tranexamic acid among patients undergoing cesarean delivery who were at high risk of postpartum hemorrhage."	9.22	Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery. ( Aneja, A; Hanjoora, VM; Kaur, R; Khanna, M; Sujata, N; Tobin, R, 2016)
"Nine databases were searched using variations of keywords 'tranexamic acid', 'postpartum hemorrhage' and 'cost effectiveness'."	9.12	The cost-effectiveness of tranexamic acid for treatment of postpartum hemorrhage: A systematic review. ( Aziz, S; Comrie-Thomson, L; Homer, CSE; Rossiter, S; Scott, N; Vogel, JP; Wilson, AN, 2021)
"The aim of this study is critically to review the available evidence regarding the use, efficacy and safety of tranexamic acid in the management of hemorrhage during pregnancy and for prevention and treatment of postpartum hemorrhage."	8.87	Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. ( Kadir, RA; Peitsidis, P, 2011)
"To evaluate the hemostatic effects of tranexamic acid (TXA) ex vivo in women with pre-eclampsia."	8.31	Evaluating the hemostatic effects of tranexamic acid in women with pre-eclampsia. ( Chigbu, CO; Nwagha, TU; Okoye, HC; Onoh, RC; Onwusulu, DN; Othman, M, 2023)
"The administration of tranexamic acid to a theoretical cohort of 100,000 women would prevent 11 maternal deaths, 6 postpartum laparotomies after vaginal delivery, and 112 reoperations after cesarean delivery."	8.12	Tranexamic acid for the treatment of postpartum hemorrhage: a cost-effectiveness analysis. ( Caughey, AB; D'Souza, R; Howard, DC; Jones, AE; Lai, J; Skeith, A, 2022)
"To check the quality of oxytocin and tranexamic acid-two recommended products for prevention and treatment of postpartum hemorrhage (PPH)-used in facilities taking part in an implementation research project to improve PPH diagnosis and management."	8.12	Quality of oxytocin and tranexamic acid for the prevention and treatment of postpartum hemorrhage in Kenya, Nigeria, South Africa, and Tanzania. ( Alwy Al-Beity, FM; Ammerdorffer, A; Beeson, L; Coomarasamy, A; Devall, AJ; Galadanci, H; Gallos, ID; Gülmezoglu, AM; Hofmeyr, GJ; Lambert, P; Mammoliti, KM; Qureshi, Z; Rushwan, S; Singata-Madliki, M; Timms, R; Wright, P, 2022)
"The objective of this review is to evaluate the effectiveness of intravenous administration of tranexamic acid (TXA) within three hours of birth in mothers with a diagnosis of postpartum hemorrhage (PPH)."	7.91	Tranexamic acid as adjuvant treatment for postpartum hemorrhage: a systematic review protocol. ( Bonanno, LS; Fahrenholtz, CG; Martin, JB, 2019)
"When used in conjunction with the standard of care, 1 g intravenous (IV) tranexamic acid given 1 to 3 hours after delivery is associated with a significant reduction in maternal mortality from postpartum hemorrhage (PPH) (strength of recommendation: A, randomized controlled trial [RCT] and Cochrane review)."	7.91	Does tranexamic acid reduce mortality in women with postpartum hemorrhage? ( Dresang, L; Kredit, S; Vellardita, L, 2019)
"The World Maternal Antifibrinolytic trial demonstrated that tranexamic acid administered during postpartum hemorrhage reduces hemorrhage-related mortality and laparotomies."	7.91	Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis. ( Einerson, BD; Shainker, SA; Sudhof, LS, 2019)
"Recent results show a protective effect of tranexamic acid on death due to bleeding in patients with postpartum hemorrhage in low- and middle-resource countries."	7.85	The effect of tranexamic acid on blood loss and maternal outcome in the treatment of persistent postpartum hemorrhage: A nationwide retrospective cohort study. ( Bloemenkamp, KWM; Caram-Deelder, C; Eikenboom, J; Gillissen, A; Henriquez, DDCA; van den Akker, T; van der Bom, JG; van Roosmalen, J; Wind, M; Zwart, JJ, 2017)
"Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e."	7.68	Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993)
"Treatment with the fibrinolytic inhibitor tranexamic acid was investigated in 12 women with vaginal bleeding in the second half of pregnancy."	7.66	Effects of tranexamic acid on the coagulation and fibrinolytic systems in pregnancy complicated by placental bleeding. ( Bonnar, J; Walzman, M, 1982)
"Tranexamic acid has been found to be both effective and safe for decreasing maternal mortality in women with postpartum hemorrhage, and prophylactic use of tranexamic acid may decrease the need for packed red blood cell transfusions and/or uterotonics."	7.01	Preventing postpartum hemorrhage with combined therapy rather than oxytocin alone. ( Eke, AC; Federspiel, JJ; Jones, AJ, 2023)
"Bleeding is the leading cause of maternal mortality in the world."	6.82	Tranexamic acid for prevention of bleeding in cesarean delivery: An overview of systematic reviews. ( Boet, S; Burns, JK; Deng, MX; Edwards, W; Etherington, C; Hurskainen, T; Martin Calderon, L; Moher, D, 2022)
"Tranexamic acid (TXA) has been investigated as a potential adjunct therapy to uterotonics within this setting."	6.58	Tranexamic Acid for Prevention and Treatment of Postpartum Hemorrhage: An Update on Management and Clinical Outcomes. ( Ahmadzia, HK; James, AH; Katler, QS; Phillips, JM, 2018)
"Placenta previa affects approximately 4 per 1000 pregnancies and increases the risk of antepartum bleeding, emergent preterm labour and emergency caesarean sections."	5.91	Use of tranexamic acid (TXA) to reduce preterm birth and other adverse obstetrical outcomes among pregnant individuals with placenta previa: a systematic review protocol. ( Muldoon, KA; Seguin, N; Visintini, S; Walker, M, 2023)
"Tranexamic acid (TXA) has been shown to reduce PPH complications although it is not routinely recommended for use as prophylaxis to date."	5.91	Tranexamic acid for the prevention of postpartum hemorrhage: a cost-effectiveness analysis. ( Ahmadzia, HK; Dazelle, WDH; Ebner, MK; Kazma, J; Potarazu, SN, 2023)
"Prophylactic use of tranexamic acid during cesarean delivery did not lead to a significantly lower risk of a composite outcome of maternal death or blood transfusion than placebo."	5.69	Tranexamic Acid to Prevent Obstetrical Hemorrhage after Cesarean Delivery. ( Bailit, JL; Chauhan, SP; Clifton, RG; Dalton, W; Grobman, WA; Gyamfi-Bannerman, C; Longo, M; Macones, GA; Metz, TD; Pacheco, LD; Parry, S; Rood, K; Rouse, DJ; Saade, GR; Salazar, A; Simhan, HN; Thorp, JM; Tita, ATN; Weiner, SJ, 2023)
"This study aims to illustrate the impact of applying the tranexamic acid impregnated in a gelatin sponge between the anterior rectus sheath and the Rectus Abdominis muscle during Cesarean section (CS) in minimizing rectus sheath hematoma (RHS) in women treated with Warfarin."	5.69	Role of tranexamic acid-soaked gelatin sponge in minimizing rectus sheath hematoma after cesarean section in women treated with warfarin, a simple tool for high-risk cases, a randomized controlled trial. ( Hany, A; Mansour, A; Nabil, M; Sediek, M, 2023)
"Tranexamic acid was administered for menorrhagia and resumed later for labor and continued into the postpartum period since antifibrinolytics have been the mainstay in the management of PAI-1 deficiency."	5.56	The utility of thromboelastography and tranexamic acid in plasminogen activator inhibitor deficiency during pregnancy: a rare case report. ( Hammer, RD; Laziuk, K; Prabhakaran, N, 2020)
"Tranexamic acid (TXA) is an antifibrinolytic pharmacologic agent with demonstrated effectiveness for reducing the incidence of death from blood loss following trauma and major surgery."	5.56	The Use of Tranexamic Acid to Prevent Postpartum Hemorrhage. ( Mielke, RT; Obermeyer, S, 2020)
"The American College of Obstetricians and Gynecologists states that the current data are insufficient to recommend tranexamic acid prophylaxis for postpartum hemorrhage."	5.51	Tranexamic acid for prevention of hemorrhage in elective repeat cesarean delivery-a randomized study. ( Duryea, EL; Eddins, MM; Klucsarits, SE; Leveno, KJ; McIntire, DD; Nelson, DB; Ogunkua, OT, 2022)
"Although prophylactic tranexamic acid administration after cesarean delivery resulted in a lower incidence of calculated estimated blood loss of >1000 mL or red cell transfusion by day 2, its failure to reduce the incidence of hemorrhage-related secondary clinical outcomes (TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery trial) makes its use questionable."	5.51	Tranexamic acid for the prevention of blood loss after cesarean among women with twins: a secondary analysis of the TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery randomized clinical trial. ( Azria, E; Benard, A; Bohec, C; Bouchghoul, H; Bretelle, F; Chauleur, C; Daniel, V; Darsonval, A; de Marcillac, F; Deneux-Tharaux, C; Desbrière, R; Froeliger, A; Fuchs, F; Gallot, D; Gauchotte, E; Georget, A; Haddad, B; Kayem, G; Korb, D; Le Lous, M; Le Ray, C; Legendre, G; Letouzey, V; Madar, H; Mattuizzi, A; Mottet, N; Parant, O; Perrotin, F; Regueme, S; Roussillon, C; Rozenberg, P; Salomon, LJ; Sananès, N; Sénat, MV; Sentilhes, L; Vardon, D; Verspyck, E; Winer, N, 2022)
"Bleeding was successfully treated using the antifibrinolytic agent tranexamic acid."	5.42	Tranexamic Acid for Hyperfibrinolytic Hemorrhage During Conservative Management of Placenta Percreta. ( Gembruch, U; Merz, WM; Pötzsch, B; Rühl, H; Schröder, L, 2015)
"The evidence that early tranexamic acid treatment reduces postpartum hemorrhage deaths has major implications for obstetrical care worldwide."	5.41	Tranexamic acid for bleeding: Much more than a treatment for postpartum hemorrhage. ( Brenner, A; Roberts, I; Shakur-Still, H, 2023)
"Tranexamic acid is a cost-effective intervention for the prevention of postpartum hemorrhage among women who undergo cesarean delivery, but the evidence to support its use is conflicting."	5.41	Tranexamic acid for the prevention of blood loss after cesarean section: an updated systematic review and meta-analysis of randomized controlled trials. ( Ahmad, AB; Ayyan, M; Azeem, S; Cheema, HA; Ehsan, M; Hussain, A; Laganà, AS; Mikuš, M; Nashwan, AJ; Shahid, A, 2023)
"To conduct the first-ever systematic review and meta-analysis of randomized controlled trials (RCTs) on the antihemorrhagic utility and safety of tranexamic acid (TXA) versus misoprostol for management (prevention and/or treatment) of postpartum hemorrhage (PPH)."	5.41	Tranexamic acid versus misoprostol for management of postpartum hemorrhage: A systematic review and meta-analysis of randomized controlled trials. ( Abdulmalik, NA; Abu-Zaid, A; Abuzaid, M; Albadawi, MI; Alblewi, H; Albouq, B; Alomar, O; Alsehaimi, SO; Alyousef, A; Baradwan, S; Bukhari, IA; Ghazi, A; Khadawardi, K; Salem, H, 2023)
"Cervical pregnancy is a rare life-threatening form of ectopic pregnancy and when it occurs, it is challenging to decide the management options."	5.40	Cervical ectopic pregnancy managed with methotrexate and tranexamic acid: A case report. ( Arowojolu, AO; Ogunbode, OO, 2014)
"An antifibrinolytic agent that blocks lysine-binding sites on plasminogen molecules, tranexamic acid reduces bleeding-related mortality in women with postpartum hemorrhage (PPH), especially administered fairly soon after delivery."	5.34	TRAAP2 - TRAnexamic Acid for Preventing postpartum hemorrhage after cesarean delivery: a multicenter randomized, doubleblind, placebo- controlled trial - a study protocol. ( Daniel, V; Deneux-Tharaux, C; Sentilhes, L, 2020)
" This trial assessed the efficacy, safety, and acceptability of oral TXA when used as an adjunct to sublingual misoprostol to treat postpartum hemorrhage (PPH) following vaginal delivery."	5.34	A double-blind, randomized controlled trial to explore oral tranexamic acid as adjunct for the treatment for postpartum hemorrhage. ( Abbas, D; Diop, A; Martin, R; Ngoc, NTN; Razafi, A; Tuyet, HTD; Winikoff, B, 2020)
"To investigate the effect of adjunctive intravenous tranexamic acid (TA) on blood loss during cesarean section (CS) in patients with placenta previa undergone bilateral uterine arteryligation (BUAL)."	5.30	Bilateral uterine artery ligation plus intravenous tranexamic acid during cesarean delivery for placenta previa: a randomized double-blind controlled trial. ( Abbas, AM; Sallam, HF; Shady, NW, 2019)
"This study was designed to compare the effect of intravenous tranexamic acid (TXA) and prostaglandin analogue on reducing PPH resulted from uterine atony in women undergoing C section or vaginal delivery."	5.27	The Effect of Tranexamic Acid on Preventing Post-partum Hemorrhage Due to Uterine Atony: A Triple-blind Randomized Clinical Trial. ( Ahmadi, M; Nikbakht, R; Zargar, M, 2018)
"The use of tranexamic acid reduces mortality due to postpartum hemorrhage."	5.27	Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery. ( Azria, E; Bohec, C; Chrétien, JM; Daniel, V; Darsonval, A; Deneux-Tharaux, C; Deruelle, P; Desbrière, R; Doret-Dion, M; Ducarme, G; Fuchs, F; Huissoud, C; Kayem, G; Le Ray, C; Perrotin, F; Seco, A; Sénat, MV; Sentilhes, L; Vardon, D; Winer, N, 2018)
"Abruptio placentae is known to have a bad prognosis for the fetus."	5.26	Abruptio placentae--treatment with the fibrinolytic inhibitor tranexamic acid. ( Astedt, B; Nilsson, IM; Svanberg, L, 1980)
"During the third stage of labor, oxytocin and tranexamic acid, oxytocin and misoprostol, oxytocin and methylergometrine, or carbetocin is recommended for the prevention of postpartum hemorrhage after vaginal delivery."	5.22	Evidence-based labor management: third stage of labor (part 5). ( Angarita, AM; Berghella, V, 2022)
"Tranexamic acid (TXA) effectively reduces bleeding in women with postpartum hemorrhage (PPH) in hospital settings."	5.22	Tranexamic Acid for Postpartum Hemorrhage Treatment in Low-Resource Settings: A Rapid Scoping Review. ( Bar-Zeev, S; Schulte-Hillen, C; Tran, NT; Zeck, W, 2022)
"To assess whether a policy of routine administration of high-dose tranexamic acid (TA) at the diagnosis of postpartum hemorrhage (PPH) reduces blood loss after vaginal birth."	5.22	Policy of high-dose tranexamic acid for treating postpartum hemorrhage after vaginal delivery. ( Bouet, PE; Descamps, P; Gillard, P; Legendre, G; Ruiz, V; Sentilhes, L, 2016)
"To assess the effects of tranexamic acid among patients undergoing cesarean delivery who were at high risk of postpartum hemorrhage."	5.22	Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery. ( Aneja, A; Hanjoora, VM; Kaur, R; Khanna, M; Sujata, N; Tobin, R, 2016)
"In this double-blind randomised controlled trial, 120 women with a singleton pregnancy were randomly allocated to receive either one gram intravenous TA or placebo in addition to 10 IU oxytocin after delivery of the fetus."	5.20	The effect of prophylactic intravenous tranexamic acid on blood loss after vaginal delivery in women at low risk of postpartum haemorrhage: a double-blind randomised controlled trial. ( Abbasalizadeh, F; Mirghafourvand, M; Mohammad-Alizadeh, S; Shirdel, M, 2015)
"Nine databases were searched using variations of keywords 'tranexamic acid', 'postpartum hemorrhage' and 'cost effectiveness'."	5.12	The cost-effectiveness of tranexamic acid for treatment of postpartum hemorrhage: A systematic review. ( Aziz, S; Comrie-Thomson, L; Homer, CSE; Rossiter, S; Scott, N; Vogel, JP; Wilson, AN, 2021)
" Systematic review and meta-analysis to determine the bleeding rates associated with tranexamic acid, desmopressin, platelet transfusion, plasma transfusion and recombinant activated factor VII, for patients with unclassified bleeding disorders undergoing surgery, childbirth or with menorrhagia."	5.12	Management of surgery, menorrhagia and child-birth for patients with unclassified bleeding disorders: a systematic review of cohort studies. ( Desborough, MJR; Doree, C; Lowe, GC; Obaji, S; Thomas, W, 2021)
" The highest-quality evidence is for the use of tranexamic acid in postpartum hemorrhage, which has been shown to decrease bleeding-related mortality in women without bleeding disorders."	4.98	Inherited Bleeding Disorders in the Obstetric Patient. ( Bannow, BS; Konkle, BA, 2018)
"This review summarizes the background, current evidence and recommendations with regard to the role of fibrinogen, tranexamic acid, prothrombin complex concentrate, desmopressin, and recombinant factor VIIa in the treatment of patients with postpartum hemorrhage."	4.91	Hemostatic resuscitation in postpartum hemorrhage - a supplement to surgery. ( Afshari, A; Albrechtsen, CK; Ekelund, K; Hanke, G; Stensballe, J; Wikkelsøe, A, 2015)
"The aim of this study is critically to review the available evidence regarding the use, efficacy and safety of tranexamic acid in the management of hemorrhage during pregnancy and for prevention and treatment of postpartum hemorrhage."	4.87	Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. ( Kadir, RA; Peitsidis, P, 2011)
"The use of tranexamic acid for postpartum hemorrhage has entered obstetrical practice globally with the evidence-based expectation of saving lives."	4.31	Tranexamic acid at cesarean delivery: drug-error deaths. ( Bishop, DG; Coomarasamy, A; Devall, AJ; Fawcus, S; Gallos, ID; Hofmeyr, GJ; Moran, NF; Morris, E; Oladapo, OT; Shakur-Still, H; Widmer, M, 2023)
"The use of tranexamic acid for postpartum hemorrhage has entered obstetrical practice globally with the evidence-based expectation of saving lives."	4.31	Tranexamic acid at cesarean delivery: Drug-error deaths. ( Bishop, DG; Coomarasamy, A; Devall, AJ; Fawcus, S; Gallos, ID; Hofmeyr, GJ; Moran, NF; Morris, E; Oladapo, OT; Shakur-Still, H; Widmer, M, 2023)
"The use of tranexamic acid for postpartum hemorrhage has entered obstetrical practice globally with the evidence-based expectation of saving lives."	4.31	Tranexamic acid at cesarean delivery: drug-error deaths. ( Bishop, DG; Coomarasamy, A; Devall, AJ; Fawcus, S; Gallos, ID; Hofmeyr, GJ; Moran, NF; Morris, E; Oladapo, OT; Shakur-Still, H; Widmer, M, 2023)
"This prospective cohort study was based on data from the Tranexamic Acid for Preventing Postpartum Hemorrhage after Cesarean Delivery (TRAAP2) trial, a multicenter, randomized, placebo-controlled trial that took place from March 2018 through January 2020 (23 months)."	4.31	Association Between Surgeon Gender and Maternal Morbidity After Cesarean Delivery. ( Bénard, A; Bouchghoul, H; Deneux-Tharaux, C; Georget, A; Madar, H; Sentilhes, L, 2023)
"Nationally, a higher percentage of patients received tranexamic acid without a postpartum hemorrhage diagnosis compared with previous studies, and the western region of the United States had an overall increased use of tranexamic acid during delivery compared with previous years."	4.31	An update to tranexamic acid trends during the peripartum period in the United States, 2019 to 2021. ( Ahmadzia, HK; Dazelle, WDH; Litman, EA; Sterling, EK, 2023)
"To evaluate the hemostatic effects of tranexamic acid (TXA) ex vivo in women with pre-eclampsia."	4.31	Evaluating the hemostatic effects of tranexamic acid in women with pre-eclampsia. ( Chigbu, CO; Nwagha, TU; Okoye, HC; Onoh, RC; Onwusulu, DN; Othman, M, 2023)
"Treatment with tranexamic acid (TxA) significantly reduces maternal death due to postpartum hemorrhage."	4.12	The effect of prophylactic use of tranexamic acid for cesarean section. ( Binyamin, Y; Erez, O; Frank, D; Frenkel, A; Gruzman, I; Heesen, M; Ioscovich, A; Lerman, S; Orbach-Zinger, S; Zlotnik, A, 2022)
"The administration of tranexamic acid to a theoretical cohort of 100,000 women would prevent 11 maternal deaths, 6 postpartum laparotomies after vaginal delivery, and 112 reoperations after cesarean delivery."	4.12	Tranexamic acid for the treatment of postpartum hemorrhage: a cost-effectiveness analysis. ( Caughey, AB; D'Souza, R; Howard, DC; Jones, AE; Lai, J; Skeith, A, 2022)
"To check the quality of oxytocin and tranexamic acid-two recommended products for prevention and treatment of postpartum hemorrhage (PPH)-used in facilities taking part in an implementation research project to improve PPH diagnosis and management."	4.12	Quality of oxytocin and tranexamic acid for the prevention and treatment of postpartum hemorrhage in Kenya, Nigeria, South Africa, and Tanzania. ( Alwy Al-Beity, FM; Ammerdorffer, A; Beeson, L; Coomarasamy, A; Devall, AJ; Galadanci, H; Gallos, ID; Gülmezoglu, AM; Hofmeyr, GJ; Lambert, P; Mammoliti, KM; Qureshi, Z; Rushwan, S; Singata-Madliki, M; Timms, R; Wright, P, 2022)
"The use of tranexamic acid for postpartum hemorrhage has entered obstetrical practice globally with the evidence-based expectation of saving lives."	4.12	Tranexamic acid at cesarean delivery: drug-error deaths. ( Bishop, DG; Coomarasamy, A; Devall, AJ; Fawcus, S; Gallos, ID; Hofmeyr, GJ; Moran, NF; Morris, E; Oladapo, OT; Shakur-Still, H; Widmer, M, 2022)
"This study aimed to determine the optimal tranexamic acid dose needed to prevent postpartum hemorrhage."	4.02	Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women. ( Ahmadzia, HK; Berger, JS; Gobburu, JVS; Guo, D; James, AH; Li, S; Luban, NLC; Miszta, A; van den Anker, J; Wolberg, AS, 2021)
"Tranexamic acid is a cheap and easy to use drug for the treatment and prevention of bleeding."	4.02	[Tranexamic acid: widely applicable, few risks]. ( Meijer, K; Stein-Wit, MA, 2021)
"The objective of this review is to evaluate the effectiveness of intravenous administration of tranexamic acid (TXA) within three hours of birth in mothers with a diagnosis of postpartum hemorrhage (PPH)."	3.91	Tranexamic acid as adjuvant treatment for postpartum hemorrhage: a systematic review protocol. ( Bonanno, LS; Fahrenholtz, CG; Martin, JB, 2019)
"When used in conjunction with the standard of care, 1 g intravenous (IV) tranexamic acid given 1 to 3 hours after delivery is associated with a significant reduction in maternal mortality from postpartum hemorrhage (PPH) (strength of recommendation: A, randomized controlled trial [RCT] and Cochrane review)."	3.91	Does tranexamic acid reduce mortality in women with postpartum hemorrhage? ( Dresang, L; Kredit, S; Vellardita, L, 2019)
"We recognized a correlation between the publication of the WOMAN trial and the administration of tranexamic acid at an early time-point in all standard operating procedures of the participating institutions to treat postpartum hemorrhage."	3.91	Influence of the WOMAN trial on national wide standard operating procedures for treatment of postpartum hemorrhage. ( Jennewein, L; Louwen, F; Möllmann, CJ; Raddatz, LM; Raimann, FJ; Sonntagbauer, M; Weber, CF; Zacharowski, K, 2019)
"The World Maternal Antifibrinolytic trial demonstrated that tranexamic acid administered during postpartum hemorrhage reduces hemorrhage-related mortality and laparotomies."	3.91	Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis. ( Einerson, BD; Shainker, SA; Sudhof, LS, 2019)
"Recent results show a protective effect of tranexamic acid on death due to bleeding in patients with postpartum hemorrhage in low- and middle-resource countries."	3.85	The effect of tranexamic acid on blood loss and maternal outcome in the treatment of persistent postpartum hemorrhage: A nationwide retrospective cohort study. ( Bloemenkamp, KWM; Caram-Deelder, C; Eikenboom, J; Gillissen, A; Henriquez, DDCA; van den Akker, T; van der Bom, JG; van Roosmalen, J; Wind, M; Zwart, JJ, 2017)
" We sought to determine the impact of tranexamic acid and ɛ-aminocaproic acid on in vitro clotting properties in pregnancy."	3.85	Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect? ( Ahmadzia, HK; Grotegut, CA; Hoffman, MR; James, AH; Lockhart, EL; Murtha, AP; Swamy, GK; Thomas, SM; Welsby, IJ, 2017)
" In postpartal period an excellent control of bleeding was obtained by regularly administering FVIII concentrate for several days as well by concomitant use of tranexamic acid and oral contraceptive pills in the next 6 weeks."	3.85	Pregnancy and delivery in a woman with severe haemophilia A. ( Antic, DA; Bodrozic, JN; Djunic, IS; Lekovic, DR; Miljic, PS; Mitrovic, MM; Petronijevic, MA; Petronijevic-Vrzic, SM, 2017)
" A rapid recourse to prostaglandins (sulprostone in France) may reverse uterine atony."	3.83	Major obstetric hemorrhage. ( Le Gouez, A; Mercier, FJ, 2016)
"In cases of placental abruption complicated with disseminated intravascular coagulation, intrapartum administration of coagulation factors can simultaneously promote effective labor and correct hypofibrinogenemia, enabling minimally invasive vaginal delivery."	3.80	Intrapartum anti-disseminated intravascular coagulation therapy leading to successful vaginal delivery following intrauterine fetal death caused by placental abruption: a case report. ( Baba, K; Era, S; Honda, M; Matsunaga, S; Seki, H; Takai, Y, 2014)
"Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e."	3.68	Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993)
"Treatment with the fibrinolytic inhibitor tranexamic acid was investigated in 12 women with vaginal bleeding in the second half of pregnancy."	3.66	Effects of tranexamic acid on the coagulation and fibrinolytic systems in pregnancy complicated by placental bleeding. ( Bonnar, J; Walzman, M, 1982)
"Delays in the detection or treatment of postpartum hemorrhage can result in complications or death."	3.30	Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage. ( Akter, S; Althabe, F; Alwy Al-Beity, F; Ammerdorffer, A; Arends, E; Aswat, A; Beeson, L; Bohren, MA; Coomarasamy, A; Devall, A; Evans, C; Fawcus, S; Forbes, G; Galadanci, H; Gallos, I; Gülmezoglu, M; Gwako, G; Hemming, K; Hofmeyr, GJ; Horne, I; Latthe, P; Lissauer, D; Lorencatto, F; Mammoliti, KM; Martin, J; Meher, S; Middleton, L; Miller, S; Moran, N; Muhammad, S; Mwampashi, A; Nausheen, S; Okore, J; Oladapo, OT; Osoti, A; Podesek, M; Qureshi, Z; Roberts, T; Sheikh, L; Shennan, A; Sindhu, KN; Singata-Madliki, M; Smith, JM; Timms, R; Wakili, AA; Weeks, A; Widmer, M; Williams, E; Yunas, I, 2023)
"Tranexamic acid (TXA) is a life-saving treatment for women with PPH."	3.30	Tranexamic acid by the intramuscular or intravenous route for the prevention of postpartum haemorrhage in women at increased risk: a randomised placebo-controlled trial (I'M WOMAN). ( Arribas, M; Bello, A; Brenner, A; Chaudhri, R; Javid, K; Kayani, A; Muganyizi, P; Olayemi, O; Roberts, I; Shakur-Still, H, 2023)
"Tranexamic acid (TXA) is a useful drug for prevention of PPH and merits evaluation in Nigeria, where PPH is the leading cause of maternal death (25%) and severe maternal morbidity."	3.11	Tranexamic acid for reducing blood loss following vaginal delivery: a double-blind randomized controlled trial. ( Dimejesi, BI; Igboke, FN; Lawani, LO; Obi, VO, 2022)
"Preoperative TXA is safe and effective in reducing blood loss during and after high-risk CD."	3.11	Safety and efficacy of preoperative tranexamic acid in reducing intraoperative and postoperative blood loss in high-risk women undergoing cesarean delivery: a randomized controlled trial. ( Al-Asmar, A; Al-Mohamady, M; El Mahy, M; Maged, AM; Rund, NMA; Shalaby, MA, 2022)
" Pharmacokinetic-pharmacodynamic modelling of these data might identify the best pharmacodynamic monitoring criteria and the optimal tranexamic acid dosing regimen for treatment of postpartum haemorrhage."	3.11	Tranexamic acid dose-response relationship for antifibrinolysis in postpartum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study. ( Allorge, D; Broisin, F; Constant, B; Ducloy-Bouthors, AS; Duhamel, A; Faraoni, D; Favier, R; Ghesquiere, L; Gilliot, S; Gouez, AL; Hennart, B; Jeanpierre, E; Keita-Meyer, H; Kyheng, M; Lebuffe, G; Moyanotidou, G; Odou, P; Peynaud, E; Rigouzzo, A; Susen, S; Turbelin, A, 2022)
"The purpose of the present study was to find the effects of TXA on the amount of bleeding following vaginal delivery and its adverse effects."	3.11	Effects of tranexamic acid on the amount of bleeding following vaginal delivery and its adverse effects: a double-blind placebo controlled randomized clinical trial. ( Dadkhah, F; Kashanian, M; Sheikhansari, N; Tabatabaei, N, 2022)
"Tranexamic acid has been found to be both effective and safe for decreasing maternal mortality in women with postpartum hemorrhage, and prophylactic use of tranexamic acid may decrease the need for packed red blood cell transfusions and/or uterotonics."	3.01	Preventing postpartum hemorrhage with combined therapy rather than oxytocin alone. ( Eke, AC; Federspiel, JJ; Jones, AJ, 2023)
"Tranexamic acid has been found to be a good choice for reducing blood loss during and after delivery in Africa regardless of the mode of delivery."	3.01	Use of tranexamic acid in decreasing blood loss during and after delivery among women in Africa: a systematic review and meta-analysis. ( Abdurke, M; Ahmed, F; Alemu, A; Amare, G; Amin, A; Balcha, T; Balis, B; Bekele, H; Debella, A; Degefa, M; Eshetu, B; Eyeberu, A; Getachew, A; Getachew, T; Habte, S; Lemi, M; Mohammed, A; Musa, I; Negash, A; Tefera, T; Yadeta, E, 2023)
"Tranexamic acid (TXA) has been shown to reduce blood loss and blood product transfusion requirements."	3.01	Effective tranexamic acid concentration for 95% inhibition of tissue-type plasminogen activator-induced hyperfibrinolysis in full-term pregnant women: a prospective interventional study. ( Faraoni, D; Lechien, A; Van der Linden, P, 2021)
"The primary outcome was postpartum hemorrhage, defined as a calculated estimated blood loss greater than 1000 ml or receipt of a red-cell transfusion within 2 days after delivery."	3.01	Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery. ( Azria, E; Benard, A; Bohec, C; Bretelle, F; Chauleur, C; Daniel, V; Darsonval, A; de Marcillac, F; Deneux-Tharaux, C; Desbrière, R; Fuchs, F; Gallot, D; Gauchotte, E; Georget, A; Haddad, B; Kayem, G; Korb, D; Le Lous, M; Le Ray, C; Legendre, G; Letouzey, V; Madar, H; Mattuizzi, A; Mottet, N; Parant, O; Perrotin, F; Regueme, S; Roussillon, C; Rozenberg, P; Salomon, LJ; Sananès, N; Sénat, MV; Sentilhes, L; Vardon, D; Verspyck, E; Winer, N, 2021)
"Hemorrhage is a leading cause of death after trauma and childbirth."	2.94	Risk factors for blood transfusion in traumatic and postpartum hemorrhage patients: Analysis of the CRASH-2 and WOMAN trials. ( Bates, I; Bello, A; Chaudhri, R; Kolin, DA; Roberts, I; Shakur-Still, H, 2020)
" TA efficiency and optimal dosage in haemorrhagic caesarean section (CS) has not been yet determined."	2.87	Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial. ( Allorge, D; Baptiste, AS; Bouthors, AS; Duhamel, A; Hennart, B; Jeanpierre, E; Lannoy, D; Saidi, I; Simon, E; Susen, S, 2018)
"No deep venous thrombosis or other severe complications had occurred."	2.84	Intra-articular Application is More Effective Than Intravenous Application of Tranexamic Acid in Total Knee Arthroplasty: A Prospective Randomized Controlled Trial. ( Wang, J; Wang, Q; Zhang, X, 2017)
"Tranexamic acid (TXA) has been shown to be a safe, effective and inexpensive therapeutic option for the treatment of PPH, however, its use prophylactically in mitigating the risk of PPH is unknown."	2.84	Protocol for a pilot, randomised, double-blinded, placebo-controlled trial of prophylactic use of tranexamic acid for preventing postpartum haemorrhage (TAPPH-1). ( Alam, A; Au, S; Barrett, J; Bopardikar, A; Callum, J; Choi, S; Kiss, A, 2017)
"Bleeding is the leading cause of maternal mortality in the world."	2.82	Tranexamic acid for prevention of bleeding in cesarean delivery: An overview of systematic reviews. ( Boet, S; Burns, JK; Deng, MX; Edwards, W; Etherington, C; Hurskainen, T; Martin Calderon, L; Moher, D, 2022)
"Tranexamic acid (TA) has been proposed for preventing or treating primary postpartum haemorrhage (PPH), which is the leading cause of maternal morbidity and mortality worldwide."	2.82	Tranexamic acid for the prevention and the treatment of primary postpartum haemorrhage: a systematic review. ( Casarin, J; Cromi, A; Ferrari, FA; Franchi, M; Garzon, S; Ghezzi, F; Raffaelli, R; Uccella, S, 2022)
" Future pharmacodynamic analyses will focus on the appropriateness of TXA dosing regimens with regard to the intensity of fibrinolysis in catastrophic obstetric events."	2.82	The role of tranexamic acid in the management of postpartum haemorrhage. ( Bouthors, AS; Deneux-Tharaux, C; Gilliot, S; Hennart, B; Jeanpierre, E; Lebuffe, G; Odou, P; Sentilhes, L, 2022)
"The frequency of postpartum hemorrhage > 500 mL was also lower in the experimental group (4, 1."	2.78	Can intravenous injection of tranexamic acid be used in routine practice with active management of the third stage of labor in vaginal delivery? A randomized controlled study. ( Ark, C; Asıcıoğlu, O; Besımoglu, B; Gungorduk, K; Tekirdağ, Aİ; Yıldırım, G, 2013)
"Tranexamic acid was more effective than placebo in short-term treatment of irregular uterine bleeding/spotting associated with DMPA use."	2.74	The effect of tranexamic acid for treatment irregular uterine bleeding secondary to DMPA use. ( Senthong, AJ; Taneepanichskul, S, 2009)
"Postpartum hemorrhage is the number one cause of severe morbidity during hospitalization for birth, despite hospital, state, and national initiatives."	2.72	Goals for Collaborative Management of Obstetric Hemorrhage. ( Baird, SM; Kennedy, MBB; Martin, S, 2021)
"Neonatal bleeding was described in 6 affected male neonates, mostly after instrumental delivery or emergency CS, but insufficient information was provided to reliably investigate neonatal outcome in relation to management."	2.72	Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review. ( Bloemenkamp, KWM; Driessens, MHE; Duvekot, JJ; Eikenboom, J; Kruip, MJHA; Lely, AT; Makelburg, ABU; Mauser-Bunschoten, EP; Middeldorp, JM; Nieuwenhuizen, L; Peters, M; Punt, MC; Schutgens, REG; van Galen, KPM; Waning, ML, 2021)
" While most studies to date have focused on empirical and one-size-fit-all dosing of TXA, more selective and individualized treatment protocols (possibly guided by functional coagulation assays) are needed to pave the way for safer and more effective use of this inexpensive and widely used medication."	2.72	Tranexamic acid and obstetric hemorrhage: give empirically or selectively? ( Javidroozi, M; Sentilhes, L; Shander, A, 2021)
"The occurrences of postpartum hemorrhage (blood lose > or = 400 ml) were 6."	2.70	[Clinical study on the efficacy of tranexamic acid in reducing postpartum blood lose: a randomized, comparative, multicenter trial]. ( Shi, C; Yang, H; Zheng, S, 2001)
"TXA concentrations of 10-15 mg/l may be suitable targets for pharmacokinetic studies, although TXA concentrations above 5 mg/l may also be effective."	2.61	What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies. ( Medcalf, RL; Picetti, R; Roberts, I; Shakur-Still, H; Standing, JF, 2019)
"For the treatment of postpartum hemorrhage, early use of TXA has the potential to reduce mortality."	2.61	Next Generation Medical Management of Postpartum Hemorrhage. ( Ahmadzia, HK; Phillips, JM; van den Anker, JN, 2019)
"Tranexamic acid (TXA) has been used to treat peripartum hemorrhage, while preoperative use of TXA in cesarean section (CS) remains controversial."	2.61	Prophylactic use of tranexamic acid reduces blood loss and transfusion requirements in patients undergoing cesarean section: A meta-analysis. ( He, L; Liu, S; Wang, Y, 2019)
"In women with postpartum hemorrhage, the need to transfuse a large amount of blood products is frequent."	2.58	Postpartum Hemorrhage: Management of Massive Transfusion. ( DeLoughery, TG; Jackson, DL, 2018)
"Tranexamic acid (TXA) has been investigated as a potential adjunct therapy to uterotonics within this setting."	2.58	Tranexamic Acid for Prevention and Treatment of Postpartum Hemorrhage: An Update on Management and Clinical Outcomes. ( Ahmadzia, HK; James, AH; Katler, QS; Phillips, JM, 2018)
" The effectiveness of treatment methods and the optimal dosage of misoprostol are research priorities."	2.53	Preventing deaths due to haemorrhage. ( Hofmeyr, GJ; Qureshi, Z, 2016)
"Tranexamic acid (TA), which is an antifibrinolytic agent that is used widely to prevent and treat haemorrhage, merits evaluation to assess whether it meets these criteria."	2.52	Tranexamic acid for preventing postpartum haemorrhage. ( Cluver, C; Hofmeyr, GJ; Novikova, N, 2015)
"The morbidity and mortality of postpartum hemorrhage (PPH) in women with an underlying bleeding disorder requires vigilance by the hematologist."	2.52	An update on the management of bleeding disorders during pregnancy. ( Kouides, PA, 2015)
"Tranexamic acid (TXA) is a possible prophylactic treatment for the prevention of PPH."	2.52	Prophylactic Use of Tranexamic Acid for Postpartum Bleeding Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Alam, A; Choi, S, 2015)
"Tranexamic acid, which is an antifibrinolytic that is used widely to prevent and treat haemorrhage, merits evaluation to assess whether it meets these criteria."	2.46	Tranexamic acid for preventing postpartum haemorrhage. ( Hofmeyr, GJ; Novikova, N, 2010)
"Tranexamic acid was usually added for mucosal surgery."	2.41	Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. ( Griffioen, A; Harrington, C; Lee, CA; Nitu-Whalley, IC, 2001)
"Hereditary angioneurotic edema (HAE) is an autosomal dominant disease caused by a deficiency of a complement regulatory protein, the C1INH."	2.38	[Clinical contribution to the problem of correlations between hereditary angioneurotic edema and pregnancy]. ( Barrile, A; Bonanno, D; Crisafi, A; Ferlazzo, B; Ferrari, U; Quattrocchi, P; Sorge, R, 1990)
"Perioperative prophylactic treatment for high-bleeding-risk surgery in patients with severe FXI deficiency is based on fresh frozen plasma (FFP) transfusions or FXI concentrate (where available)."	1.91	[PERIOPERATIVE MANAGEMENT OF AN ADOLESCENT GIRL WITH SEVERE FACTOR XI DEFICIENCY AND INHIBITORS]. ( Berger-Achituv, S; Keren-Politansky, A; Mandel-Shorer, N; Oren-Malek, L; Revel-Vilk, S, 2023)
"Placenta previa affects approximately 4 per 1000 pregnancies and increases the risk of antepartum bleeding, emergent preterm labour and emergency caesarean sections."	1.91	Use of tranexamic acid (TXA) to reduce preterm birth and other adverse obstetrical outcomes among pregnant individuals with placenta previa: a systematic review protocol. ( Muldoon, KA; Seguin, N; Visintini, S; Walker, M, 2023)
"Tranexamic acid (TXA) has been shown to reduce PPH complications although it is not routinely recommended for use as prophylaxis to date."	1.91	Tranexamic acid for the prevention of postpartum hemorrhage: a cost-effectiveness analysis. ( Ahmadzia, HK; Dazelle, WDH; Ebner, MK; Kazma, J; Potarazu, SN, 2023)
"Although pregnancy has been considered a trigger, it may have variable effect on frequency of attacks of HAE."	1.72	Management of pregnancy in hereditary angioedema in a resource constrained setting: Our experience at Chandigarh, North India. ( Barman, P; Chawla, S; Chopra, S; Jindal, AK; Kaur, A; Longhurst, H; Mahajan, S; Sikka, P; Singh, S; Tyagi, R, 2022)
"To describe maternal deaths from postpartum hemorrhage (PPH) in Kenya by secondary analysis of the Kenya Confidential Enquiry into Maternal Deaths (CEMD) database and clinical audit of a sample of those deaths, and to identify the perceived challenges to implementing country-specific PPH guidelines."	1.72	A synthesis of clinical and health system bottlenecks to implementing new WHO postpartum hemorrhage recommendations: Secondary data analysis of the Kenya Confidential Enquiry into Maternal Deaths 2014-2017. ( Allott, H; Ameh, CA; Dickinson, F; Godia, P; Meka, RJ; West, F, 2022)
"Postpartum Hemorrhage is still the leading cause of maternal mortality."	1.62	[Obstetric Surgery with High Risk of Postpartum Hemorrhage in a Jehovah's Witness]. ( Carp, M; Lança, F; Maurício, S, 2021)
"To examine UK haemophilia centre registration patterns and current practice for UBD patients."	1.62	Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders. ( Desborough, M; Downes, K; Evans, G; Gidley, G; Lowe, G; MacDonald, S; O'Donnell, JS; Obaji, S; Palmer, B; Pinto, F; Thomas, W, 2021)
"Tranexamic acid was administered for menorrhagia and resumed later for labor and continued into the postpartum period since antifibrinolytics have been the mainstay in the management of PAI-1 deficiency."	1.56	The utility of thromboelastography and tranexamic acid in plasminogen activator inhibitor deficiency during pregnancy: a rare case report. ( Hammer, RD; Laziuk, K; Prabhakaran, N, 2020)
"Tranexamic acid (TXA) is an antifibrinolytic pharmacologic agent with demonstrated effectiveness for reducing the incidence of death from blood loss following trauma and major surgery."	1.56	The Use of Tranexamic Acid to Prevent Postpartum Hemorrhage. ( Mielke, RT; Obermeyer, S, 2020)
"Tranexamic acid concentration was measured using liquid chromatography system coupled with tandem mass spectrometry."	1.56	Hypothesis for a partially non urinary elimination of tranexamic acid in haemorrhagic caesarean section: Traces pilot pharmacokinetic study: Pharmacokinetics of tranexamic acid in obstetrics. ( Ducloy-Bouthors, AS; Gilliot, S; Hennart, B; Jeanne, M; Lebuffe, G; Loingeville, F; Odou, P, 2020)
"Uterine atony is the primary cause of post-partum haemorrhage."	1.51	[Post-partum transfusion: The view of the anaesthetist in a delivery room]. ( Langlois, C, 2019)
"The authors describe a case of immune thrombocytopenic purpura presenting with spontaneous gingival haemorrhage in pregnancy."	1.51	Immune thrombocytopenic purpura presenting with spontaneous gingival haemorrhage in pregnancy. ( Dunphy, L; Williams, R, 2019)
"Tranexamic acid appears to be a safe and effective option in the treatment of obstetric hemorrhage."	1.46	Tranexamic Acid for the Management of Obstetric Hemorrhage. ( Chiossi, G; Costantine, MM; Hankins, GDV; Pacheco, LD; Saad, AF; Saade, GR, 2017)
"The delivery was complicated by postpartum hemorrhage, which resolved with the addition of uterotonic agents."	1.43	Management of Labour and Delivery in a Patient With Acquired Factor VII Deficiency With Inhibitor: A Case Report. ( Andrews, J; Dolan, S; Matei, A; Rivard, GÉ, 2016)
"Anaphylaxis during pregnancy is rare but life threatening to both mother and fetus."	1.42	Anaphylaxis-induced hyperfibrinolysis in pregnancy. ( Browning, RM; Truong, HT, 2015)
"Bleeding was successfully treated using the antifibrinolytic agent tranexamic acid."	1.42	Tranexamic Acid for Hyperfibrinolytic Hemorrhage During Conservative Management of Placenta Percreta. ( Gembruch, U; Merz, WM; Pötzsch, B; Rühl, H; Schröder, L, 2015)
"To assess the management of postpartum hemorrhage (PPH) by anaesthesiologists in Pays de la Loire area."	1.40	[Declarative survey about postpartum haemorrhage management by anaesthesiologists in Pays de la Loire area (France): what's the adherence to clinical practice guidelines?]. ( Bouvet, C; Branger, B; Granry, JC; Lehousse, T; Sentilhes, L, 2014)
"Cervical pregnancy is a rare life-threatening form of ectopic pregnancy and when it occurs, it is challenging to decide the management options."	1.40	Cervical ectopic pregnancy managed with methotrexate and tranexamic acid: A case report. ( Arowojolu, AO; Ogunbode, OO, 2014)
"We present a case of suspected amniotic fluid embolism that presented with sudden respiratory arrest associated with haemodynamic compromise during a non-elective caesarean delivery."	1.39	Hyperfibrinolysis diagnosed by rotational thromboelastometry in a case of suspected amniotic fluid embolism. ( Bloor, M; Collins, NF; McDonnell, NJ, 2013)
"Transfusion therapy in postpartum hemorrhage (PPH) traditionally has been modeled after precedents set in the Vietnam and Korean wars."	1.38	Postpartum hemorrhage management in 2012: predicting the future. ( Green, D; Keith, L; Onwuemene, O, 2012)
"Glanzmann's thrombasthenia is a congenitally acquired platelet disorder with an autosomal recessive mode of inheritance."	1.33	Pregnancy in a patient of Glanzmann's thrombasthenia. ( Chanana, C; Deka, D; Malhotra, N, 2006)
"Abruptio placentae is known to have a bad prognosis for the fetus."	1.26	Abruptio placentae--treatment with the fibrinolytic inhibitor tranexamic acid. ( Astedt, B; Nilsson, IM; Svanberg, L, 1980)

Research

Studies (286)

Authors

Clinical Trials (41)

Trial Overview

Trial Outcomes

Blood Volume Loss

Timeframe	Studies, this research(%)	All Research%
pre-1990	12 (4.20)	18.7374
1990's	5 (1.75)	18.2507
2000's	18 (6.29)	29.6817
2010's	141 (49.30)	24.3611
2020's	110 (38.46)	2.80

Authors	Studies
Hurskainen, T	1
Deng, MX	1
Etherington, C	1
Burns, JK	1
Martin Calderon, L	1
Moher, D	1
Edwards, W	1
Boet, S	1
Bellos, I	2
Pergialiotis, V	2
Brignardello-Petersen, R	1
El Alayli, A	1
Husainat, N	1
Kalot, MA	1
Shahid, S	1
Aljabirii, Y	1
Britt, A	1
Alturkmani, H	1
El-Khechen, H	1
Motaghi, S	1
Roller, J	1
Abdul-Kadir, R	3
Couper, S	1
Kouides, P	1
Lavin, M	1
Ozelo, MC	1
Weyand, A	1
James, PD	1
Connell, NT	1
Flood, VH	1
Mustafa, RA	1
Smith, CT	1
Arnolds, DE	2
Lim, G	1
Hemani, M	1
Parihar, K	1
Gervais, N	1
Morais, M	1
Sentilhes, L	27
Deneux-Tharaux, C	23
Roberts, I	20
Ker, K	8
Ferrari, FA	1
Garzon, S	1
Raffaelli, R	1
Cromi, A	1
Casarin, J	1
Ghezzi, F	1
Uccella, S	1
Franchi, M	1
Jindal, AK	1
Barman, P	1
Chawla, S	1
Kaur, A	1
Tyagi, R	1
Sikka, P	1
Chopra, S	1
Mahajan, S	1
Longhurst, H	1
Singh, S	1
Ogunkua, OT	1
Duryea, EL	1
Nelson, DB	1
Eddins, MM	1
Klucsarits, SE	1
McIntire, DD	1
Leveno, KJ	1
Obermeyer, S	2
Mielke, RT	2
Lederhos, HL	1
Binyamin, Y	1
Orbach-Zinger, S	1
Gruzman, I	1
Frenkel, A	1
Lerman, S	1
Zlotnik, A	1
Frank, D	1
Ioscovich, A	1
Erez, O	1
Heesen, M	3
Madar, H	9
Howard, DC	1
Jones, AE	1
Skeith, A	1
Lai, J	1
D'Souza, R	1
Caughey, AB	1
Igboke, FN	1
Obi, VO	1
Dimejesi, BI	1
Lawani, LO	1
Shalaby, MA	1
Maged, AM	2
Al-Asmar, A	1
El Mahy, M	1
Al-Mohamady, M	1
Rund, NMA	1
Brenner, A	5
Balogun, E	4
Bello, FA	1
Chaudhri, R	7
Fleming, C	1
Javaid, K	3
Kayani, A	4
Lubeya, MK	2
Mansukhani, R	3
Olayemi, O	2
Prowse, D	3
Vwalika, B	2
Shakur-Still, H	16
Abu-Zaid, A	2
Baradwan, S	2
Alshahrani, MS	1
Bakhsh, H	1
Badghish, E	1
Khadawardi, K	2
AlRasheed, MA	1
Turkistani, A	1
AlNaim, NF	1
AlNaim, LF	1
Fodaneel, M	1
AbuAlsaud, FS	1
Jamjoom, MZ	1
Tulbah, M	1
Almugbel, M	1
Alomar, O	2
Al-Jundi, H	1
Allam, HS	1
Alabdrabalamir, S	1
Salem, H	2
Al-Badawi, IA	1
Tran, NT	2
Schulte-Hillen, C	2
Bar-Zeev, S	2
Chidanyika, A	1
Zeck, W	2
Angarita, AM	1
Berghella, V	5
Le Lous, M	2
Sénat, MV	4
Winer, N	4
Rozenberg, P	2
Kayem, G	3
Verspyck, E	2
Fuchs, F	3
Azria, E	3
Gallot, D	2
Korb, D	2
Desbrière, R	3
Le Ray, C	4
Chauleur, C	2
de Marcillac, F	2
Perrotin, F	5
Parant, O	2
Salomon, LJ	2
Gauchotte, E	2
Bretelle, F	2
Sananès, N	2
Bohec, C	3
Mottet, N	2
Legendre, G	4
Letouzey, V	2
Haddad, B	2
Vardon, D	4
Mattuizzi, A	3
Froeliger, A	3
Bouchghoul, H	2
Daniel, V	5
Regueme, S	2
Roussillon, C	2
Georget, A	3
Darsonval, A	4
Benard, A	4
Grassin-Delyle, S	2
Muhunthan, K	2
Ahmadzia, HK	10
Faraoni, D	4
Arribas, M	4
Ammerdorffer, A	2
Rushwan, S	1
Timms, R	2
Wright, P	1
Beeson, L	2
Devall, AJ	5
Mammoliti, KM	2
Alwy Al-Beity, FM	1
Galadanci, H	2
Hofmeyr, GJ	9
Singata-Madliki, M	2
Qureshi, Z	3
Lambert, P	1
Gallos, ID	5
Coomarasamy, A	6
Gülmezoglu, AM	3
Ameh, CA	1
Meka, RJ	1
West, F	1
Dickinson, F	1
Allott, H	1
Godia, P	1
Lu, C	1
Corbett, C	1
Elliott, JE	1
Evans, D	1
Seifert, SM	1
Goobie, SM	1
Fields, KG	1
Farber, MK	1
Strauss, ER	1
VanDyck, K	1
Mazzeffi, MA	1
Jones, AJ	1
Federspiel, JJ	1
Eke, AC	2
Castle, D	1
Desborough, MJR	2
Kemp, M	1
Lowe, G	2
Thomas, W	3
Obaji, S	3
Ducloy-Bouthors, AS	9
Gilliot, S	4
Kyheng, M	1
Turbelin, A	1
Keita-Meyer, H	2
Rigouzzo, A	1
Moyanotidou, G	1
Constant, B	1
Broisin, F	2
Gouez, AL	1
Favier, R	1
Peynaud, E	1
Ghesquiere, L	1
Lebuffe, G	4
Duhamel, A	5
Allorge, D	3
Susen, S	6
Hennart, B	6
Jeanpierre, E	6
Odou, P	4
Moran, NF	4
Bishop, DG	4
Fawcus, S	5
Morris, E	4
Widmer, M	5
Oladapo, OT	6
Eyeberu, A	3
Getachew, T	3
Amare, G	3
Yadeta, E	3
Lemi, M	3
Bekele, H	3
Negash, A	3
Degefa, M	3
Balcha, T	3
Balis, B	3
Eshetu, B	3
Habte, S	3
Abdurke, M	3
Alemu, A	3
Mohammed, A	3
Ahmed, F	3
Musa, I	3
Getachew, A	3
Amin, A	3
Tefera, T	3
Debella, A	3
Bouthors, AS	4
Joshi, BN	1
Shetty, SS	1
Moray, KV	1
Chaurasia, H	1
Sachin, O	1
Mandel-Shorer, N	1
Oren-Malek, L	1
Keren-Politansky, A	1
Berger-Achituv, S	1
Revel-Vilk, S	1
Beaumont, D	5
Litman, EA	2
Ma, P	1
Miran, SA	1
Nelson, SJ	1
Lee, SH	1
Kwek, ME	1
Tagore, S	1
Wright, A	1
Ku, CW	1
Teong, ACA	1
Tan, AWM	1
Lim, SWC	1
Yen, DYT	1
Ang, CYX	1
Sultana, R	1
Lim, CHF	1
Mathur, D	1
Mathur, M	1
Patel, S	1
Seguin, N	1
Visintini, S	1
Muldoon, KA	1
Walker, M	1
Sterling, EK	1
Dazelle, WDH	2
Alam, AQ	1
Barrett, J	2
Callum, J	2
Kaustov, L	1
Au, S	2
Fleet, A	1
Kiss, A	2
Choi, S	3
Geer, A	1
Lamy, E	1
Israr, N	1
Mazhar, SB	1
Urien, S	1
Bouazza, N	1
Foissac, F	1
Carrington, L	1
Barrow, C	1
Onandia, JG	1
Pacheco, LD	3
Clifton, RG	1
Saade, GR	3
Weiner, SJ	1
Parry, S	1
Thorp, JM	1
Longo, M	1
Salazar, A	1
Dalton, W	1
Tita, ATN	1
Gyamfi-Bannerman, C	1
Chauhan, SP	1
Metz, TD	1
Rood, K	1
Rouse, DJ	2
Bailit, JL	1
Grobman, WA	1
Simhan, HN	1
Macones, GA	1
Okoye, HC	1
Othman, M	1
Nwagha, TU	1
Onwusulu, DN	1
Onoh, RC	1
Chigbu, CO	1
Ebner, MK	1
Kazma, J	1
Potarazu, SN	1
Gallos, I	1
Devall, A	1
Martin, J	1
Middleton, L	1
Alwy Al-Beity, F	1
Moran, N	1
Sheikh, L	1
Gwako, G	1
Osoti, A	1
Aswat, A	1
Sindhu, KN	1
Podesek, M	1
Horne, I	1
Yunas, I	1
Okore, J	1
Arends, E	1
Wakili, AA	1
Mwampashi, A	1
Nausheen, S	1
Muhammad, S	1
Latthe, P	1
Evans, C	1
Akter, S	1
Forbes, G	1
Lissauer, D	1
Meher, S	1
Weeks, A	1
Shennan, A	1
Williams, E	1
Roberts, T	1
Lorencatto, F	1
Bohren, MA	1
Miller, S	2
Althabe, F	1
Gülmezoglu, M	2
Smith, JM	1
Hemming, K	1
Bouvet, L	2
Rackelboom, T	1
Morau, E	1
Yang, F	1
Wang, H	1
Shen, M	1
Bosilah, AH	1
Eldesouky, E	1
Alghazaly, MM	1
Farag, E	1
Sultan, EEK	1
Alazazy, H	1
Mohamed, A	2
Ali, SMS	1
Elsror, AGA	1
Mahmoud, M	1
Abd Elhalim, AEM	1
Kamel, MA	1
Abd-ElGawad, M	1
Sayed, FM	1
Bakry, MS	1
Cheema, HA	1
Ahmad, AB	1
Ehsan, M	1
Shahid, A	3
Ayyan, M	1
Azeem, S	1
Hussain, A	1
Nashwan, AJ	1
Mikuš, M	1
Laganà, AS	1
Boatin, AA	1
Ngonzi, J	1
Ogah, CO	1
Anikwe, CC	1
Ikeoha, CC	1
Dimejesi, OB	1
Okorochukwu, BC	1
Esike, CO	1
Buchholz, A	1
Hansen, K	1
Rodel, R	1
Dawoud, M	1
Al-Husseiny, M	1
Helal, O	1
Elsherbini, M	1
Abdel-Rasheed, M	1
Sediek, M	2
Petit, S	1
Albouq, B	1
Ghazi, A	1
Bukhari, IA	1
Alyousef, A	1
Abdulmalik, NA	1
Alblewi, H	1
Alsehaimi, SO	1
Albadawi, MI	1
Abuzaid, M	1
Hany, A	1
Mansour, A	1
Nabil, M	1
Al-Dardery, NM	1
Abdelwahab, OA	1
Abouzid, M	1
Albakri, K	1
Elkhadragy, A	1
Katamesh, BE	1
Hamamreh, R	1
Mohd, AB	1
Abdelaziz, A	1
Khaity, A	1
Muganyizi, P	1
Javid, K	1
Bello, A	2
Langlois, C	1
Fahrenholtz, CG	1
Bonanno, LS	1
Martin, JB	1
Fitzpatrick, KE	1
van den Akker, T	2
Bloemenkamp, KWM	3
Kristufkova, A	1
Li, Z	1
Schaap, TP	1
Sullivan, EA	1
Tuffnell, D	1
Knight, M	1
Dresang, L	1
Kredit, S	1
Vellardita, L	1
Prabhakaran, N	1
Laziuk, K	1
Hammer, RD	1
Helito, CP	1
Bonadio, MB	1
Sobrado, MF	1
Giglio, PN	1
Pécora, JR	1
Camanho, GL	1
Demange, MK	1
Zakhari, A	1
Sanders, AP	1
Solnik, MJ	1
Diop, A	1
Abbas, D	1
Ngoc, NTN	1
Martin, R	1
Razafi, A	1
Tuyet, HTD	1
Winikoff, B	1
Balakumar, S	1
Navaratnaraja, TS	1
Premakrishna, S	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Use of Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery[NCT03856164]	Phase 2/Phase 3	110 participants (Actual)	Interventional	2019-06-17	Completed
The Value of Tranxemic Acid to Reduce Intraoperative Blood Loss During Elective Cesarean Sections in High Risk Women: A Randomized Controlled Trial[NCT03820206]		160 participants (Actual)	Interventional	2019-01-31	Completed
Tranexamic Acid for the Prevention of Postpartum Bleeding in Women With Anaemia: an International, Randomised, Double-blind, Placebo Controlled Trial.[NCT03475342]	Phase 3	15,000 participants (Anticipated)	Interventional	2019-08-24	Recruiting
Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery: a Multicenter Randomized Double Blind Placebo Controlled Therapeutic and Pharmaco-biological Dose Ranging Study (TRACES) for Its Optimal Benefit/Risk[NCT02797119]	Phase 4	225 participants (Actual)	Interventional	2016-03-15	Terminated (stopped due to Study will be stopped due to the impossibility of reaching the objective of inclusions within a reasonable time frame and taking into account the recommendations of the international WOMAN study)
Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty - Randomized Prospective Study[NCT02152917]	Phase 4	45 participants (Anticipated)	Interventional	2014-02-28	Recruiting
Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer[NCT04360629]		151 participants (Actual)	Interventional	2020-06-03	Completed
TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery :a Multicenter Randomised, Double Blind Placebo Controlled Trial (TRAAP2)[NCT03431805]	Phase 3	4,574 participants (Actual)	Interventional	2018-03-03	Completed
Double-blind, Randomized Controlled Trial to Assess the Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage[NCT02805426]	Phase 4	260 participants (Actual)	Interventional	2016-10-31	Completed
Does Oral Administration of Tranexamic Acid in Anterior Cruciate Ligament Arthroscopic Surgery Reduce Postoperative Haemarthrosis and Improve Functional Prognosis?[NCT04855877]	Phase 4	104 participants (Anticipated)	Interventional	2021-07-06	Recruiting
Tranexamic Acid for the Treatment of Postpartum Haemorrhage: An International Randomised, Double Blind, Placebo Controlled Trial[NCT00872469]	Phase 3	20,060 participants (Actual)	Interventional	2009-05-31	Completed
A Large Randomised Placebo Controlled Trial Among Trauma Patients With, or at Risk of, Significant Haemorrhage, of the Effects of Antifibrinolytic Treatment on Death and Transfusion Requirement[NCT00375258]	Phase 3	20,211 participants (Actual)	Interventional	2005-05-31	Completed
Prevention of Postpartum Hemorrhage: Identifying Pregnant Women at Risk and Determining the Safe and Effective Use of Tranexamic Acid Using State-of-the-art Pharmacokinetic/Pharmacodynamics Modeling[NCT03287336]	Phase 2	30 participants (Anticipated)	Interventional	2018-01-02	Active, not recruiting
Management of Postpartum Haemorrhage and Effect of Geographic Region: A Secondary Analysis of the World Maternal Antifibrinolytic (WOMAN) Trial[NCT03166839]		20,060 participants (Actual)	Observational	2009-03-31	Completed
Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491]	Phase 3	11,000 participants (Actual)	Interventional	2018-03-15	Completed
TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma[NCT05713630]	Phase 3	130 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
Prevention of Postpartum Hemorrhage With Tranexamic Acid (TXA)[NCT03326596]	Phase 4	1,000 participants (Anticipated)	Interventional	2018-04-20	Recruiting
Tranexamic Acid to Prevent Bleeding After Endoscopic Resection of Large Colorectal Polyps: A Pilot Project[NCT04559880]	Phase 4	25 participants (Actual)	Interventional	2020-09-10	Active, not recruiting
Prophylactic Use of Tranexamic Acid for Preventing Postpartum Hemorrhage: A Randomized, Double-blinded, Placebo-controlled Pilot Trial[NCT03069859]	Phase 2	31 participants (Actual)	Interventional	2018-03-06	Active, not recruiting
Efficacy of Tranexamic Acid (TXA) in Humerus ORIF[NCT05802238]	Phase 2	130 participants (Anticipated)	Interventional	2023-04-12	Recruiting
The Efficacy and Safety of Intrauterine Misoprostol Versus Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Delivery in Patients With Placenta Previa: A Randomized Controlled Trial[NCT05340205]	Phase 4	81 participants (Actual)	Interventional	2022-05-04	Completed
The Efficacy and Safety of Tranexamic Acid Versus Uterotonic Agents in Reducing Blood Loss During and After Cesarean Section Among High-risk Patients: a Comparative Study[NCT06060327]		444 participants (Anticipated)	Interventional	2023-10-15	Not yet recruiting
Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery: a Multicenter Randomised Double Blind Placebo Controlled Trial[NCT02302456]	Phase 3	4,079 participants (Actual)	Interventional	2015-02-28	Completed
Precise Application of Topical Tranexamic Acid to Enhance Endoscopic Hemostasis for Peptic Ulcer Bleeding: A Randomized Controlled Study[NCT05248321]		60 participants (Actual)	Interventional	2022-03-24	Completed
Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study (TAPPAS): A Randomized, Placebo-controlled Double Blind Trial[NCT02806024]	Phase 4	14 participants (Actual)	Interventional	2016-11-30	Completed
Evaluation of a Transfusion Therapy Using Whole Blood Versus Fractionated Blood Products in the Management of Coagulopathy in Patients Admitted to Hospital for Acute Traumatic Hemorrhage[NCT04431999]	Phase 3	200 participants (Anticipated)	Interventional	2021-12-04	Recruiting
Evaluation of the Minimum Concentration of Tranexamic Acid Required to Inhibit Fibrinolysis in a Population of Pregnant Women at Term.[NCT02579941]		40 participants (Actual)	Interventional	2015-11-30	Completed
Prophylactic Use of Topical Tranexamic Acid to Aid Surgical Haemostasis During Caesarean Sections in Parturients With Moderate to High Risk of Bleeding[NCT02492087]	Phase 3	84 participants (Anticipated)	Interventional	2015-08-31	Recruiting
Comparative Study For Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section: A Randomised Controlled Trial[NCT02739815]	Phase 4	200 participants (Actual)	Interventional	2016-04-30	Completed
Tranexamic Acid Versus Novel Uterine Cooling Technique in Reducing Blood Loss and Incidence of Postpartum Hemorrhage at Caesarean Section[NCT02780245]	Phase 4	100 participants (Actual)	Interventional	2016-06-30	Completed
A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss[NCT03793153]		99 participants (Actual)	Interventional	2018-12-19	Completed
IV Tranexamic Acid Prior to Hysterectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial[NCT02911831]	Early Phase 1	71 participants (Actual)	Interventional	2016-11-30	Completed
Randomized Control Trial Investigating for Prophylactic Tranexamic Acid Use at Time of Minimally Invasive Myomectomies[NCT04311073]	Phase 3	50 participants (Anticipated)	Interventional	2020-06-20	Recruiting
Single Centre Randomised Controlled Trial to Assess the Effect of the Addition of Twenty-four Hours of Oral Tranexamic Acid Post-operatively to a Single Intra-operative Intravenous Dose of Tranexamic Acid on Calculated Blood Loss Following Primary Hip and[NCT03690037]	Phase 4	1,089 participants (Actual)	Interventional	2016-07-07	Completed
The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128]	Phase 4	50 participants (Anticipated)	Interventional	2021-08-01	Not yet recruiting
Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage[NCT05554211]	Phase 2	30 participants (Anticipated)	Interventional	2022-07-12	Recruiting
Effects of Tranexamic Acid on Post Partum Hemorrhage by Uterine Atony After Cesarean Section Delivery: a Randomized, Placebo Controlled Trial.[NCT01599468]	Phase 4	74 participants (Actual)	Interventional	2011-07-31	Completed
[NCT01338454]	Phase 3	450 participants (Actual)	Interventional	2011-03-31	Completed
Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study[NCT00740116]	Phase 4	100 participants (Actual)	Interventional	2008-03-31	Completed
National Study of Moderate and Severe Von Willebrand Disease in the Netherlands[NCT00510042]		1,100 participants (Anticipated)	Observational	2007-07-31	Completed
Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458]		265 participants (Actual)	Observational	2012-11-05	Active, not recruiting
Efficacy of Tranexamic Acid in Reducing Blood Loss During and After Caesarean Section[NCT02350179]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2014-06-30	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Total blood volume loss will be calculated in milliliters. (NCT03856164)
Timeframe: 24 hours postpartum.

D-Dimer (µg/mL)

Intervention	milliliters (Mean)
Tranexamic Acid	2274
Placebo	2407

Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.

Fibrinogen (mg/dL)

Intervention	µg/mL (Mean)
	Before Surgery	After Delivery	P.O.D. 1
Placebo	4.0	3.8	4.3
Tranexamic Acid	2.9	2.4	2.1

Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.

Plasminogen Activator Inhibitor-Type-1 (Units/mL)

Intervention	mg/dL (Mean)
	Before Surgery	After Delivery	P.O.D. 1
Placebo	550.7	484.9	525.4
Tranexamic Acid	563.5	499.6	527.4

Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.

Rotational Thromboelastometry INTEM and EXTEM Clotting Time

Intervention	IU/mL (Mean)
	Before Surgery	After Delivery	P.O.D. 1
Placebo	61.7	63.3	22.1
Tranexamic Acid	81.8	67.0	20.7

Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter). (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.

Rotational Thromboelastometry INTEM, EXTEM, FIBTEM Maximum Clot Firmness

Intervention	seconds (Mean)
	Before Surgery INTEM Clotting Time	After Delivery INTEM Clotting Time	P.O.D. 1 INTEM Clotting Time	Before Surgery EXTEM Clotting Time	After Delivery EXTEM Clotting Time	P.O.D. 1 EXTEM Clotting Time
Placebo	150.5	140.7	141.2	56.1	56.3	50.2
Tranexamic Acid	149.7	137.4	145.1	54.0	54.9	49.3

Tissue Plasminogen Activator Antigen (ng/mL)

Intervention	millimeter (Mean)
	Before Surgery INTEM Maximum Clot Firmness	After Delivery INTEM Maximum Clot Firmness	P.O.D. 1 INTEM Maximum Clot Firmness	Before Surgery EXTEM Maximum Clot Firmness	After Delivery EXTEM Maximum Clot Firmness	P.O.D. 1 EXTEM Maximum Clot Firmness	Before Surgery FIBTEM Maximum Clot Firmness	After Delivery FIBTEM Maximum Clot Firmness	P.O.D. 1 FIBTEM Maximum Clot Firmness
Placebo	69.4	68.4	68.8	71.2	69.6	70.4	23.9	22.0	25.0
Tranexamic Acid	69.3	68.9	68.8	70.8	69.8	70.5	24.2	22.5	25.8

Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.

Change in Hemoglobin

Intervention	ng/mL (Mean)
	Before Surgery	After Delivery	P.O.D. 1
Placebo	8.2	9.6	7.4
Tranexamic Acid	8.1	9.0	7.5

[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum

Length of Stay

Intervention	grams per deciliter (Mean)
Tranexamic Acid	-1.8
Placebo	-1.9

Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days

Number of Mothers Who Died or Had Thromboembolic Events (Venous or Arterial), Ischemic Stroke, Myocardial Infarction, New-onset Seizure Activity, or Were Admitted to the Intensive Care Unit for More Than 24 Hours

Number of Participants Who Received Open Label TXA or Other Antifibrinolytic

Intervention	days (Median)
Tranexamic Acid	3
Placebo	3

Intervention	Participants (Count of Participants)
Tranexamic Acid	35
Placebo	32

This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum

Number of Participants Who Received Surgical or Radiologic Interventions to Control Bleeding and Related Complications

Intervention	Participants (Count of Participants)
Tranexamic Acid	108
Placebo	109

This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum

Number of Participants Who Received Treatments and Interventions in Response to Bleeding and Related Complications

Intervention	Participants (Count of Participants)
Tranexamic Acid	233
Placebo	231

[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum

Number of Participants Who Were Transfused With 4 or More Units of Packed Red Blood Cells

Intervention	Participants (Count of Participants)
Tranexamic Acid	892
Placebo	986

Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum

Number of Participants Who Were Transfused With Other Blood Products

Intervention	Participants (Count of Participants)
Tranexamic Acid	20
Placebo	19

This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum

Number of Participants Who Were Treated With Uterotonics Other Than Oxytocin

Intervention	Participants (Count of Participants)
Tranexamic Acid	29
Placebo	31

This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum

Number of Participants With a Thromboembolic Event (Venous or Arterial), Ischemic Stroke, or Myocardial Infarction

Intervention	Participants (Count of Participants)
Tranexamic Acid	649
Placebo	732

[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum

Number of Participants With Estimated Blood Loss Greater Than 1 Liter During Delivery

Intervention	Participants (Count of Participants)
Tranexamic Acid	12
Placebo	13

[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour

Number of Participants With Maternal Death or Transfusion of Packed Red Blood Cells

Intervention	Participants (Count of Participants)
Tranexamic Acid	339
Placebo	368

Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner

Number of Participants With Postpartum Infectious Complications

Intervention	Participants (Count of Participants)
Tranexamic Acid	201
Placebo	233

[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum

Number of Participants With Seizure Activity That Was Not Seen Prior to Study Enrollment

Intervention	Participants (Count of Participants)
Tranexamic Acid	162
Placebo	125

This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum

Blood Transfusion (Number of Units Transfused) Intraoperatively

Intervention	Participants (Count of Participants)
Tranexamic Acid	2
Placebo	0

Total number of units of blood transfused (whole blood, platelets, cryoprecipitate, and fresh frozen plasma) intra-operatively is a secondary outcome. (NCT02806024)
Timeframe: Pulled from operative note, completed by the time of discharge.

Estimated Blood Loss (EBL)

Intervention	units (Mean)
Treatment Arm (Tranexamic Acid, or TXA)	5.2
Placebo Arm	17.6

EBL is estimated by the surgeon and anesthesia team at the completion of the surgery (cesarean delivery &/or cesarean hysterectomy). (NCT02806024)
Timeframe: 1-3 hours (will be determined at the completion of the surgery).

Median Number of Transfused Units of Red Blood Cells (RBC)

Intervention	cc (Mean)
Treatment Arm (Tranexamic Acid, or TXA)	3116
Placebo Arm	9420

Median number of red blood cells transfused among those who received RBC transfusions (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Number of Patients Receiving Blood Transfusions

Intervention	units (Median)
The Placebo Group	2
The Tranexamic Acid Group	2

Total number of RBC-transfused women in each group (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Number of Patients With Clinically or Radiologically Verified Thromboembolic Events Within 5 Weeks Postoperatively

Intervention	participants (Number)
Tranexamic Group	15
Placebo Group	22

Thromboembolic events including arterial thrombosis, muscle vein thrombosis, superficial and deep venous thrombosis. (NCT00740116)
Timeframe: From time of operation to 5 weeks postoperatively.

Number of Units of Red Blood Cells (RBC) Transfused

Intervention	Participants (Count of Participants)
Tranexamic Group	2
Placebo Group	5

Total number of red blood cells (RBC) transfused across all participants (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Perioperative Bleeding Volume

Intervention	units (Number)
Tranexamic Group	38
Placebo Group	53

Estimation of total blood loss was based on the estimation of the Hb balance method (Brecher, et al.1997) with the assumption that the body blood volume was normalised on the fifth postoperative day. The haemoglobin level was assessed preoperatively and on the fifth postoperative day. The predicted blood volume (PBV, l) was calculated according to the method described by Nadler et al. (1962), using body weight and height. The extravasation of haemoglobin was calculated taking into account allogenic transfused haemoglobin. Total blood loss perioperatively was related to the patient's preoperative haemoglobin value. Blood loss due to haematomas or a reoperation within the first five days after surgery was also considered. (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Centralized Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Intervention	milliliter (Median)
Tranexamic Group	520
Placebo Group	730

Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

Centralized Factor VIII (FVIII) Antigen (FVIII:Ag) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Intervention	IU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)	1.63

Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

Centralized Factor VIII (FVIII) Procoagulant Activity (FVIII:C) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Intervention	IU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)	3.64

Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

Centralized Von Willebrand Factor (VWF) Propeptide Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Intervention	IU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)	2.43

Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

Centralized Von Willebrand Factor Antigen (VWF:Ag) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Intervention	IU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)	7.3

Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

Local Laboratory Tests for Type 3 Von Willebrand's Disease (VWD3) Diagnosis (Composite)

Intervention	IU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)	1.29

"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)

Number of Patients With Available Local Laboratory Test for Anti-Von Willebrand Factor (Anti-VWF) Antibodies

Intervention	Participants (Count of Participants)
Type 3 Von Willebrand's Disease (VWD3)	265

Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)

Patients Experiencing Allergic Reactions During Use of Von Willebrand Factor (VWF)-Containing Concentrates

Intervention	Participants (Count of Participants)
Type 3 Von Willebrand's Disease (VWD3)	4

Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)

Number of Participants With Previous Use of Blood Products

Intervention	Participants (Count of Participants)
Type 3 Von Willebrand's Disease (VWD3)	41

Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)

Article	Year
Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature. Blood advances, 2022, 01-11, Volume: 6, Issue:1 Topics: Female; Humans; Menorrhagia; Postpartum Hemorrhage; Pregnancy; Systematic Reviews as Topic; Tranexam	2022
Tranexamic acid for obstetric hemorrhage: Prophylaxis, treatment, both, neither? Anaesthesia, critical care & pain medicine, 2021, Volume: 40, Issue:5 Topics: Antifibrinolytic Agents; Female; Hemorrhage; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Ac	2021
Tranexamic Acid Use in the Postpartum Period Since the WOMAN Trial: A Retrospective Chart Review. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2022, Volume: 44, Issue:3 Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Period; Pregnancy; Retrospecti	2022
Tranexamic acid for the prevention of postpartum hemorrhage in women undergoing cesarean delivery. American journal of obstetrics and gynecology, 2022, Volume: 226, Issue:5 Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexa	2022
Reply: Prophylactic tranexamic acid in cesarean delivery: synthesis of evidence. American journal of obstetrics and gynecology, 2022, Volume: 226, Issue:5 Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexa	2022
Management of pregnancy in hereditary angioedema in a resource constrained setting: Our experience at Chandigarh, North India. Immunobiology, 2022, Volume: 227, Issue:2 Topics: Angioedemas, Hereditary; Complement C1 Inhibitor Protein; Female; Humans; India; Pregnancy; Tranexam	2022
The Role of Perinatal Nurses in the Use of Tranexamic Acid During Postpartum Hemorrhage. Nursing for women's health, 2022, Volume: 26, Issue:1 Topics: Antifibrinolytic Agents; Female; Humans; Nurse's Role; Postpartum Hemorrhage; Pregnancy; Tranexamic	2022
The effect of prophylactic use of tranexamic acid for cesarean section. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2022, Volume: 35, Issue:25 Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Hemoglobins; Humans; Infant	2022
[What's new in obstetrics and gynecology ? About tranexamic acid for the prevention of postpartum hemorrhage]. Gynecologie, obstetrique, fertilite & senologie, 2022, Volume: 50, Issue:3 Topics: Antifibrinolytic Agents; Female; Gynecology; Humans; Obstetrics; Postpartum Hemorrhage; Pregnancy; T	2022
Tranexamic acid for the treatment of postpartum hemorrhage: a cost-effectiveness analysis. American journal of obstetrics & gynecology MFM, 2022, Volume: 4, Issue:3 Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Female; Humans; Male; Maternal Death; Postpartum Hem	2022
Postpartum haemorrhage in anaemic women: assessing outcome measures for clinical trials. Trials, 2022, Mar-18, Volume: 23, Issue:1 Topics: Anemia; Delivery, Obstetric; Female; Humans; Outcome Assessment, Health Care; Postpartum Hemorrhage;	2022
How to use heat-stable carbetocin and tranexamic acid for the prevention and treatment of postpartum haemorrhage in low-resource settings. BMJ global health, 2022, Volume: 7, Issue:4 Topics: Female; Hot Temperature; Humans; Oxytocin; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid	2022
Quality of oxytocin and tranexamic acid for the prevention and treatment of postpartum hemorrhage in Kenya, Nigeria, South Africa, and Tanzania. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2022, Volume: 158 Suppl 1 Topics: Female; Humans; Kenya; Nigeria; Oxytocin; Postpartum Hemorrhage; Pregnancy; South Africa; Tanzania;	2022
A synthesis of clinical and health system bottlenecks to implementing new WHO postpartum hemorrhage recommendations: Secondary data analysis of the Kenya Confidential Enquiry into Maternal Deaths 2014-2017. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2022, Volume: 158 Suppl 1 Topics: Data Analysis; Female; Humans; Kenya; Maternal Death; Misoprostol; Oxytocics; Postpartum Hemorrhage;	2022
Fertility-sparing surgery for diffuse adenomyosis: a narrated, stepwise approach to the Osada procedure. Fertility and sterility, 2022, Volume: 118, Issue:3 Topics: Adenomyoma; Adenomyosis; Adult; Blood Loss, Surgical; Contraceptive Agents; Female; Hemostatics; Hum	2022
Tranexamic acid for cesarean delivery: evidence of fibrinolysis? American journal of obstetrics and gynecology, 2023, Volume: 228, Issue:1 Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Female; Fibrinolysis; Humans; Pregn	2023
Tranexamic acid for cesarean delivery: induction of a regimen for postpartum hemorrhage? American journal of obstetrics and gynecology, 2023, Volume: 228, Issue:1 Topics: Antifibrinolytic Agents; Cesarean Section; Clinical Protocols; Female; Humans; Postpartum Hemorrhage	2023
Outcomes and management of pregnancy in women with bleeding disorder of unknown cause. Journal of thrombosis and haemostasis : JTH, 2022, Volume: 20, Issue:11 Topics: Deamino Arginine Vasopressin; Female; Hemophilia A; Hemostatics; Humans; Postpartum Hemorrhage; Preg	2022
Tranexamic acid at cesarean delivery: drug-error deaths. American journal of obstetrics and gynecology, 2023, Volume: 228, Issue:1 Topics: Anesthetics, Local; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage	2023
Tranexamic acid at cesarean delivery: drug-error deaths. European journal of obstetrics, gynecology, and reproductive biology, 2022, Volume: 279 Topics: Anesthesia, Spinal; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage	2022
Tranexamic acid at cesarean delivery: Drug-error deaths. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2023, Volume: 160, Issue:1 Topics: Anesthesia, Spinal; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage	2023
Tranexamic acid at cesarean delivery: drug-error deaths. BJOG : an international journal of obstetrics and gynaecology, 2023, Volume: 130, Issue:1 Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Medication Errors; Postpartum Hemorrhage;	2023
Cost-effectiveness and budget impact of adding tranexamic acid for management of post-partum hemorrhage in the Indian public health system. BMC pregnancy and childbirth, 2023, Jan-06, Volume: 23, Issue:1 Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Female; Humans; Postpartum Hemorrhage; Postpartum Pe	2023
Association Between Surgeon Gender and Maternal Morbidity After Cesarean Delivery. JAMA surgery, 2023, 03-01, Volume: 158, Issue:3 Topics: Female; Humans; Oxytocics; Oxytocin; Postpartum Hemorrhage; Pregnancy; Prospective Studies; Surgeons	2023
[PERIOPERATIVE MANAGEMENT OF AN ADOLESCENT GIRL WITH SEVERE FACTOR XI DEFICIENCY AND INHIBITORS]. Harefuah, 2023, Volume: 162, Issue:1 Topics: Adolescent; Factor XI Deficiency; Female; Hemorrhage; Humans; Pregnancy; Pregnancy Complications, He	2023
Hamostaseologie, 2023, Volume: 43, Issue:1 Topics: Cesarean Section; Female; Fibrinolysis; Humans; Pregnancy; Tranexamic Acid	2023
Recent trends in tranexamic acid use during postpartum hemorrhage in the United States. Journal of thrombosis and thrombolysis, 2023, Volume: 55, Issue:4 Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Maternal Mortality; Postpartum Hemorrhage	2023
Use of tranexamic acid (TXA) to reduce preterm birth and other adverse obstetrical outcomes among pregnant individuals with placenta previa: a systematic review protocol. BMJ open, 2023, 03-07, Volume: 13, Issue:3 Topics: Female; Humans; Infant, Newborn; Obstetric Labor Complications; Placenta; Placenta Previa; Postpartu	2023
An update to tranexamic acid trends during the peripartum period in the United States, 2019 to 2021. American journal of obstetrics & gynecology MFM, 2023, Volume: 5, Issue:6 Topics: Antifibrinolytic Agents; Female; Humans; Peripartum Period; Postpartum Hemorrhage; Pregnancy; Retros	2023
Evaluating the hemostatic effects of tranexamic acid in women with pre-eclampsia. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2023, Volume: 162, Issue:3 Topics: Body Mass Index; Female; Hemostatics; Humans; Pre-Eclampsia; Pregnancy; Tranexamic Acid	2023
Tranexamic acid for the prevention of postpartum hemorrhage: a cost-effectiveness analysis. Journal of thrombosis and thrombolysis, 2023, Volume: 56, Issue:1 Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Female; Humans; Postpar	2023
Does tranexamic acid have its place in the prevention of postpartum hemorrhage? Anaesthesia, critical care & pain medicine, 2023, Volume: 42, Issue:4 Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid	2023
Early Detection and Bundled Treatment for Postpartum Hemorrhage. The New England journal of medicine, 2023, Jul-06, Volume: 389, Issue:1 Topics: Antifibrinolytic Agents; Combined Modality Therapy; Early Diagnosis; Female; Humans; Postpartum Hemo	2023
Tranexamic acid for reduction of blood loss after Caesarean delivery: a cost-effectiveness analysis of the TRAAP2 trial. British journal of anaesthesia, 2023, Volume: 131, Issue:5 Topics: Antifibrinolytic Agents; Cesarean Section; Cost-Effectiveness Analysis; Female; Humans; Postpartum H	2023
[Post-partum transfusion: The view of the anaesthetist in a delivery room]. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2019, Volume: 26, Issue:3 Topics: Anesthetists; Attitude of Health Personnel; Blood Transfusion; Delivery Rooms; Female; Fibrinogen; H	2019
Tranexamic acid as adjuvant treatment for postpartum hemorrhage: a systematic review protocol. JBI database of systematic reviews and implementation reports, 2019, Volume: 17, Issue:8 Topics: Adjuvants, Pharmaceutic; Administration, Intravenous; Antifibrinolytic Agents; Female; Humans; Postp	2019
Risk factors, management, and outcomes of amniotic fluid embolism: A multicountry, population-based cohort and nested case-control study. PLoS medicine, 2019, Volume: 16, Issue:11 Topics: Adult; Australia; Case-Control Studies; Cohort Studies; Embolism, Amniotic Fluid; Female; France; Hu	2019
Does tranexamic acid reduce mortality in women with postpartum hemorrhage? The Journal of family practice, 2019, Volume: 68, Issue:9 Topics: Antifibrinolytic Agents; Female; Humans; Injections, Intravenous; Postpartum Hemorrhage; Pregnancy;	2019
The utility of thromboelastography and tranexamic acid in plasminogen activator inhibitor deficiency during pregnancy: a rare case report. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2020, Volume: 31, Issue:1 Topics: Adult; Female; Hemorrhagic Disorders; Humans; Plasminogen Activator Inhibitor 1; Pregnancy; Thrombel	2020
Tranexamic Acid for Postpartum Hemorrhage. American family physician, 2020, 05-01, Volume: 101, Issue:9 Topics: Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid	2020
Antifibrinolytic drugs for treating primary postpartum hemorrhage. Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, 2020, Volume: 32, Issue:3 Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid	2020
The Use of Tranexamic Acid to Prevent Postpartum Hemorrhage. Journal of midwifery & women's health, 2020, Volume: 65, Issue:3 Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Risk Factors; Tranexamic	2020
National trends in tranexamic acid use in the peripartum period, 2015-2019. Journal of thrombosis and thrombolysis, 2020, Volume: 50, Issue:3 Topics: Adult; Antifibrinolytic Agents; Female; Humans; Peripartum Period; Postpartum Hemorrhage; Pregnancy;	2020
Tranexamic acid use for postpartum hemorrhage: A survey of Illinois birthing hospitals. Journal of clinical anesthesia, 2020, Volume: 67 Topics: Antifibrinolytic Agents; Female; Hospitals; Humans; Illinois; Postpartum Hemorrhage; Pregnancy; Tran	2020
Hypothesis for a partially non urinary elimination of tranexamic acid in haemorrhagic caesarean section: Traces pilot pharmacokinetic study: Pharmacokinetics of tranexamic acid in obstetrics. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2020, Oct-01, Volume: 153 Topics: Cesarean Section; Female; Humans; Injections, Intravenous; Obstetrics; Pregnancy; Tranexamic Acid	2020
Intraoperative coagulopathy during cesarean section as an unsuspected initial presentation of COVID-19: a case report. BMC pregnancy and childbirth, 2020, Aug-24, Volume: 20, Issue:1 Topics: Adult; Antifibrinolytic Agents; Betacoronavirus; Blood Coagulation Disorders; Blood Loss, Surgical;	2020
Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID-19-A common clinical feature between a rare disorder and a new, common infection. International journal of laboratory hematology, 2020, Volume: 42, Issue:6 Topics: Betacoronavirus; Cesarean Section; Clinical Laboratory Techniques; Consanguinity; Coronavirus Infect	2020
Intramuscular tranexamic acid: a real-world application of pharmacokinetics. British journal of anaesthesia, 2021, Volume: 126, Issue:1 Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid	2021
Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women. American journal of obstetrics and gynecology, 2021, Volume: 225, Issue:1 Topics: Adult; Cesarean Section; Dose-Response Relationship, Drug; Female; Fibrin Fibrinogen Degradation Pro	2021
Implementation of a guideline of early administration of tranexamic acid for severe primary postpartum haemorrhage: a retrospective comparative study. The Australian & New Zealand journal of obstetrics & gynaecology, 2021, Volume: 61, Issue:3 Topics: Female; Hemoglobins; Humans; Hysterectomy; Postpartum Hemorrhage; Pregnancy; Retrospective Studies;	2021
Population pharmacokinetics and pharmacodynamics of Tranexamic acid in women undergoing caesarean delivery. British journal of clinical pharmacology, 2021, Volume: 87, Issue:9 Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexa	2021
[Tranexamic acid: widely applicable, few risks]. Nederlands tijdschrift voor geneeskunde, 2021, 03-25, Volume: 165 Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Female; Hemorrhage; Hemostatic Techniques; Hum	2021
[Tranexamic acid for prophylaxis of postpartum hemorrhage following cesarean delivery. Comments on the TRAAP2 study]. Der Anaesthesist, 2021, Volume: 70, Issue:11 Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexa	2021
Effect of tranexamic acid on clinical therapeutic effect and blood coagulation function of high-risk pregnant women with postpartum hemorrhage after cesarean section. Minerva medica, 2022, Volume: 113, Issue:5 Topics: Blood Coagulation; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Ac	2022
[Obstetric Surgery with High Risk of Postpartum Hemorrhage in a Jehovah's Witness]. Acta medica portuguesa, 2021, Mar-31, Volume: 34, Issue:4 Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Humans; Jehovah's Witnesses; Obstetric Surgical	2021
Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery. Reply. The New England journal of medicine, 2021, 08-05, Volume: 385, Issue:6 Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Pregnancy; Tranexamic Acid	2021
Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery. The New England journal of medicine, 2021, 08-05, Volume: 385, Issue:6 Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Pregnancy; Tranexamic Acid	2021
Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders. Journal of thrombosis and haemostasis : JTH, 2021, Volume: 19, Issue:11 Topics: Anticoagulants; Female; Hemophilia A; Humans; Pregnancy; Tranexamic Acid; United Kingdom; Venous Thr	2021
Re: Does tranexamic acid prevent postpartum haemorrhage? A systematic review of randomised controlled trials: A very welcome publication. BJOG : an international journal of obstetrics and gynaecology, 2017, Volume: 124, Issue:6 Topics: Female; Humans; Postpartum Hemorrhage; Pregnancy; Publishing; Tranexamic Acid	2017
WOMAN: reducing maternal deaths with tranexamic acid. Lancet (London, England), 2017, 05-27, Volume: 389, Issue:10084 Topics: Antifibrinolytic Agents; Double-Blind Method; Female; Humans; Hysterectomy; Maternal Death; Postpart	2017
Aortoiliac Thrombosis Following Tranexamic Acid Administration During Urgent Cesarean Hysterectomy: A Case Report. A & A case reports, 2017, Aug-01, Volume: 9, Issue:3 Topics: Adult; Antifibrinolytic Agents; Aorta, Abdominal; Balloon Occlusion; Cesarean Section; Female; Human	2017
Management of pregnancy in type 3 von Willebrand disease with alloantibodies. British journal of haematology, 2018, Volume: 182, Issue:3 Topics: Adult; Disease Management; Factor VIIa; Female; Humans; Isoantibodies; Platelet Transfusion; Pregnan	2018
Anaesthesia for abnormally invasive placenta: cell salvage and tranexamic acid. International journal of obstetric anesthesia, 2017, Volume: 32 Topics: Anesthesia; Anesthesiology; Antifibrinolytic Agents; Female; Humans; Placenta; Placenta Accreta; Pre	2017
Tranexamic Acid for the Management of Obstetric Hemorrhage. Obstetrics and gynecology, 2017, Volume: 130, Issue:4 Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid; Treatmen	2017
Administration of tranexamic acid to reduce maternal mortality related to postpartum haemorrhage: comments on the WOMAN trial. International journal of obstetric anesthesia, 2018, Volume: 33 Topics: Antifibrinolytic Agents; Female; Humans; Maternal Mortality; Postpartum Hemorrhage; Pregnancy; Trane	2018
Should we add tranexamic acid to postpartum haemorrhage protocols after the WOMAN trial publication? Anaesthesia, critical care & pain medicine, 2018, Volume: 37, Issue:4 Topics: Adult; Antifibrinolytic Agents; Clinical Trials as Topic; Evidence-Based Medicine; Female; Humans; P	2018
Tranexamic acid for post-partum haemorrhage in the WOMAN trial. Lancet (London, England), 2017, 09-30, Volume: 390, Issue:10102 Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Postpartum Period; Pregnancy; Tranex	2017
Tranexamic acid for post-partum haemorrhage in the WOMAN trial. Lancet (London, England), 2017, 09-30, Volume: 390, Issue:10102 Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Postpartum Period; Pregnancy; Tranex	2017
Tranexamic acid for post-partum haemorrhage in the WOMAN trial. Lancet (London, England), 2017, 09-30, Volume: 390, Issue:10102 Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Postpartum Period; Pregnancy; Tranex	2017
Tranexamic acid for post-partum haemorrhage in the WOMAN trial. Lancet (London, England), 2017, 09-30, Volume: 390, Issue:10102 Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Postpartum Period; Pregnancy; Tranex	2017
Tranexamic acid for post-partum haemorrhage in the WOMAN trial. Lancet (London, England), 2017, 09-30, Volume: 390, Issue:10102 Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Postpartum Period; Pregnancy; Tranex	2017
Tranexamic acid for post-partum haemorrhage in the WOMAN trial - Authors' reply. Lancet (London, England), 2017, 09-30, Volume: 390, Issue:10102 Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Postpartum Period; Pregnancy; Tranex	2017
Moving Beyond Uterotonics for the Treatment of Postpartum Hemorrhage: Lessons From the WOMAN Study. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2017, Volume: 39, Issue:12 Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemostatic Techniques; Humans; Hysterectomy; Mis	2017
Updated WHO recommendation on intravenous tranexamic acid for the treatment of post-partum haemorrhage. The Lancet. Global health, 2018, Volume: 6, Issue:1 Topics: Administration, Intravenous; Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnan	2018
The effect of tranexamic acid on blood loss and maternal outcome in the treatment of persistent postpartum hemorrhage: A nationwide retrospective cohort study. PloS one, 2017, Volume: 12, Issue:11 Topics: Adult; Female; Humans; Postpartum Hemorrhage; Pregnancy; Pregnancy Outcome; Retrospective Studies; T	2017
Tranexamic Acid for the Management of Obstetric Hemorrhage. Obstetrics and gynecology, 2017, Volume: 130, Issue:6 Topics: Antifibrinolytic Agents; Female; Hemorrhage; Humans; Pregnancy; Tranexamic Acid	2017
Intrathecal tranexamic acid - an accident waiting to happen? International journal of obstetric anesthesia, 2018, Volume: 34 Topics: Adult; Anesthetics, Local; Antifibrinolytic Agents; Bupivacaine; Drug Packaging; Female; Humans; Inj	2018
Tranexamic acid for postpartum haemorrhage: a major advance. The Lancet. Global health, 2018, Volume: 6, Issue:2 Topics: Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid	2018
Tranexamic acid to prevent post-partum haemorrhage. Blood transfusion = Trasfusione del sangue, 2018, Volume: 16, Issue:4 Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Postpartum Period; Pregnancy; Tranex	2018
[Tranexamic acid for the management of postpartum haemorrhage : current knowledge]. Revue medicale suisse, 2018, Oct-17, Volume: 14, Issue:623 Topics: Antifibrinolytic Agents; Female; Humans; Maternal Mortality; Postpartum Hemorrhage; Pregnancy; Trane	2018
Immune thrombocytopenic purpura presenting with spontaneous gingival haemorrhage in pregnancy. BMJ case reports, 2019, Jan-17, Volume: 12, Issue:1 Topics: Adult; Female; Gingival Hemorrhage; Humans; Immunoglobulins, Intravenous; Pregnancy; Pregnancy Compl	2019
Role of intravenous tranexamic acid in reducing blood loss during caesarean section: Study at tribal-dominated area hospital in Chhattisgarh, India. The journal of obstetrics and gynaecology research, 2019, Volume: 45, Issue:4 Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section;	2019
Influence of the WOMAN trial on national wide standard operating procedures for treatment of postpartum hemorrhage. Journal of gynecology obstetrics and human reproduction, 2019, Volume: 48, Issue:4 Topics: Algorithms; Antifibrinolytic Agents; Berlin; Birth Rate; Clinical Trials as Topic; Female; Humans; O	2019
Rotational thromboelastometry as a tool in the diagnosis and management of amniotic fluid embolism. International journal of obstetric anesthesia, 2019, Volume: 38 Topics: Adult; Antifibrinolytic Agents; Coagulants; Embolism, Amniotic Fluid; Female; Fibrinogen; Humans; Pr	2019
[Renal cortical necrosis after application of tranexamic acid in peripartal hemorrhage]. Deutsche medizinische Wochenschrift (1946), 2019, Volume: 144, Issue:10 Topics: Adult; Female; Humans; Kidney Cortex Necrosis; Postpartum Hemorrhage; Pregnancy; Renal Dialysis; Tra	2019
Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis. American journal of obstetrics and gynecology, 2019, Volume: 221, Issue:3 Topics: Adult; Antifibrinolytic Agents; Cost Savings; Cost-Benefit Analysis; Decision Trees; Female; Health	2019
[Management of massive bleeding in 2013: seven questions and answers]. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2013, Volume: 20, Issue:2 Topics: Acute Disease; Blood Component Transfusion; Combined Modality Therapy; Disease Management; Erythrocy	2013
Clinical transfusion practice update: haemovigilance, complications, patient blood management and national standards. The Medical journal of Australia, 2013, Sep-16, Volume: 199, Issue:6 Topics: Acute Lung Injury; Anticoagulants; Antifibrinolytic Agents; Australia; Blood Transfusion; Clinical P	2013
Healthy ethical conduct is vital. Acta obstetricia et gynecologica Scandinavica, 2014, Volume: 93, Issue:4 Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; China; Comorbidity; Computer	2014
[Declarative survey about postpartum haemorrhage management by anaesthesiologists in Pays de la Loire area (France): what's the adherence to clinical practice guidelines?]. Annales francaises d'anesthesie et de reanimation, 2014, Volume: 33, Issue:5 Topics: Adult; Anesthesiology; Blood Transfusion; Female; France; Guideline Adherence; Guidelines as Topic;	2014
Management of pregnancies in a hereditary angioedema patient after treatment with attenuated androgens since childhood. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2015, Volume: 35, Issue:1 Topics: Adult; Angioedemas, Hereditary; Antifibrinolytic Agents; Complement C1 Inhibitor Protein; Danazol; E	2015
Intrapartum anti-disseminated intravascular coagulation therapy leading to successful vaginal delivery following intrauterine fetal death caused by placental abruption: a case report. Journal of medical case reports, 2014, Dec-23, Volume: 8 Topics: Abruptio Placentae; Adult; Antifibrinolytic Agents; Coagulants; Delivery, Obstetric; Disseminated In	2014
Prophylactic tranexamic acid in low-risk parturients. Acta anaesthesiologica Scandinavica, 2015, Volume: 59, Issue:5 Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid	2015
High-dose tranexamic acid for treating postpartum haemorrhage after vaginal delivery. British journal of anaesthesia, 2015, Volume: 114, Issue:2 Topics: Adult; Antifibrinolytic Agents; Delivery, Obstetric; Female; Humans; Postpartum Hemorrhage; Pregnanc	2015
Anaphylaxis-induced hyperfibrinolysis in pregnancy. International journal of obstetric anesthesia, 2015, Volume: 24, Issue:2 Topics: Adult; Anaphylaxis; Antifibrinolytic Agents; Blood Coagulation Disorders; Bronchial Spasm; Crystallo	2015
In response to the letter by Schwarz GL et al. concerning the paper by Heesen M et al. Acta anaesthesiologica Scandinavica, 2015, Volume: 59, Issue:5 Topics: Antifibrinolytic Agents; Female; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Acid	2015
Tranexamic Acid for Hyperfibrinolytic Hemorrhage During Conservative Management of Placenta Percreta. Obstetrics and gynecology, 2015, Volume: 126, Issue:5 Topics: Adult; Antifibrinolytic Agents; Female; Fibrinolysis; Hemorrhage; Humans; Placenta Accreta; Pregnanc	2015
Cervical ectopic pregnancy managed with methotrexate and tranexamic acid: A case report. African journal of medicine and medical sciences, 2014, Volume: 43, Issue:4 Topics: Abortifacient Agents, Nonsteroidal; Adult; Antifibrinolytic Agents; Cervix Uteri; Female; Humans; Me	2014
The effectiveness of tranexamic acid at reducing postoperative blood loss following cesarean section: a systematic review of quantitative evidence protocol. JBI database of systematic reviews and implementation reports, 2015, Jul-17, Volume: 13, Issue:6 Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postoperative Hemorrhage; Pregnancy; Preg	2015
Blood-Conservation Strategies in a Blood-Refusal Parturient with Placenta Previa and Placenta Percreta. A & A case reports, 2016, Mar-01, Volume: 6, Issue:5 Topics: Adult; Bloodless Medical and Surgical Procedures; Combined Modality Therapy; Erythropoietin; Female;	2016
Beware of using tranexamic acid in parturients with eclampsia. Anaesthesia, critical care & pain medicine, 2016, Volume: 35, Issue:3 Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Critical Care; Eclampsia; Fe	2016
Tranexamic acid for preventing postpartum blood loss at cesarean delivery: is evidence sufficient? Acta obstetricia et gynecologica Scandinavica, 2016, Volume: 95, Issue:7 Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomi	2016
Evidence on the use of tranexamic acid at cesarean delivery. Acta obstetricia et gynecologica Scandinavica, 2016, Volume: 95, Issue:7 Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomi	2016
Tranexamic Acid for Prevention PPH: a Promising Drug But Today Only a Promising Drug. Transfusion medicine reviews, 2016, Volume: 30, Issue:2 Topics: Antifibrinolytic Agents; Chemoprevention; Female; Humans; Postpartum Hemorrhage; Pregnancy; Randomiz	2016
Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH. Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:1 Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Disorders; Blood Transfusion; Cardiology; Facto	2016
Management of Labour and Delivery in a Patient With Acquired Factor VII Deficiency With Inhibitor: A Case Report. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2016, Volume: 38, Issue:2 Topics: Adult; Factor VII Deficiency; Factor VIIa; Female; Hemostatics; Humans; Postpartum Hemorrhage; Pregn	2016
Prophylactic tranexamic acid in addition to uterotonics may prevent blood loss for vaginal and caesarean deliveries. Evidence-based medicine, 2016, Volume: 21, Issue:3 Topics: Antifibrinolytic Agents; Cesarean Section; Female; Humans; Oxytocics; Pregnancy; Tranexamic Acid	2016
Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema. Clinical and experimental immunology, 2016, Volume: 185, Issue:3 Topics: Adolescent; Adult; Angioedemas, Hereditary; Bradykinin; Child; Complement C1 Inhibitor Protein; Cont	2016
Major obstetric hemorrhage. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2016, Volume: 23, Issue:4 Topics: Blood Component Transfusion; Combined Modality Therapy; Dinoprostone; Factor VIIa; Female; Fibrinoge	2016
Comparison of postpartum haemorrhage guidelines: discrepancies underline our lack of knowledge. BJOG : an international journal of obstetrics and gynaecology, 2017, Volume: 124, Issue:5 Topics: Antifibrinolytic Agents; Female; Hemostatic Techniques; Humans; Oxytocics; Oxytocin; Postpartum Hemo	2017
Risk of Tranexamic Acid for Treatment of Postpartum Hemorrhage. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 69, Issue:1 Topics: Female; Humans; Postpartum Hemorrhage; Pregnancy; Risk; Tranexamic Acid	2017
In Reply to 'Risk of Tranexamic Acid for Treatment of Postpartum Hemorrhage'. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 69, Issue:1 Topics: Female; Humans; Postpartum Hemorrhage; Pregnancy; Risk; Tranexamic Acid	2017
[Transfusion strategy for patients with severe postpartum hemorrhage: a retrospective study of 47 cases]. The Pan African medical journal, 2016, Volume: 25 Topics: Adolescent; Adult; Blood Transfusion; Cesarean Section; Erythrocyte Transfusion; Factor VIIa; Female	2016
Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect? Journal of neonatal-perinatal medicine, 2017, Volume: 10, Issue:1 Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Coagulation; Case-Control Studies; Female;	2017
Pregnancy and delivery in a woman with severe haemophilia A. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2017, Volume: 28, Issue:6 Topics: Adult; Factor VIII; Female; Hemophilia A; Hemorrhage; Humans; Pregnancy; Pregnancy Complications, He	2017
[Management of menometrorrhagia in women with and without pregnancy intention: hierarchy of therapies]. Journal de gynecologie, obstetrique et biologie de la reproduction, 2008, Volume: 37 Suppl 8 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Contraceptives, Oral, Hormonal; Embolization, T	2008
The obstetric experience of women with factor XI deficiency. Acta obstetricia et gynecologica Scandinavica, 2009, Volume: 88, Issue:10 Topics: Adult; Antifibrinolytic Agents; Delivery, Obstetric; Factor XI; Factor XI Deficiency; Female; Humans	2009
Algorithm-based coagulation management of catastrophic amniotic fluid embolism. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2010, Volume: 21, Issue:1 Topics: Acidosis; Adult; Algorithms; Blood Coagulation Factors; Blood Component Transfusion; Cardiovascular	2010
Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy, 2010, Volume: 65, Issue:10 Topics: Angioedemas, Hereditary; Cohort Studies; Complement C1 Inactivator Proteins; Complement C1 Inhibitor	2010
Postpartum hemorrhage in a Jehovah's Witness patient controlled with Tisseel, tranexamic acid, and recombinant factor VIIa. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2010, Volume: 32, Issue:10 Topics: Adult; Antifibrinolytic Agents; Factor VIIa; Female; Fibrin Tissue Adhesive; Hemostatics; Humans; Hy	2010
Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery. Thrombosis and haemostasis, 2011, Volume: 106, Issue:3 Topics: Abdomen; Adult; Antifibrinolytic Agents; Cesarean Section; Cholecystectomy; Disease Progression; Dru	2011
Pregnancy-associated breast cancer: a review for the obstetrical care provider. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2011, Volume: 33, Issue:9 Topics: Factor VIIa; Female; Fibrin Tissue Adhesive; Hemostatics; Humans; Jehovah's Witnesses; Postpartum He	2011
Tranexamic acid for postpartum bleeding. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2011, Volume: 115, Issue:3 Topics: Anemia; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Postpartum Hemorrhage; Pregnancy;	2011
Successful in vitro fertilization and pregnancy in Glanzmann thrombasthenia. Haemophilia : the official journal of the World Federation of Hemophilia, 2012, Volume: 18, Issue:5 Topics: Adult; Antifibrinolytic Agents; Cesarean Section; Female; Fertilization in Vitro; Humans; Infant, Ne	2012
Management of delivery with FVIII/VWF concentrates in a pregnant woman with type 3 von Willebrand disease and alloantibodies. Thrombosis and haemostasis, 2012, Volume: 108, Issue:4 Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cesarean Section; Factor VIII; Female; Humans; In	2012
Postpartum hemorrhage management in 2012: predicting the future. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2012, Volume: 119, Issue:1 Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Fibrinogen; Humans; Point-of-Care Systems; Postp	2012
Successful pregnancy outcome after treatment with C1-inhibitor concentrate in a patient with hereditary angioedema and a history of four miscarriages. European journal of obstetrics, gynecology, and reproductive biology, 2012, Volume: 165, Issue:2 Topics: Abortion, Habitual; Adult; Complement C1 Inhibitor Protein; Danazol; Female; Hereditary Angioedema T	2012
Hyperfibrinolysis diagnosed by rotational thromboelastometry in a case of suspected amniotic fluid embolism. International journal of obstetric anesthesia, 2013, Volume: 22, Issue:1 Topics: Adult; Antifibrinolytic Agents; Blood Coagulation; Blood Coagulation Disorders; Cesarean Section; Di	2013
A comparison of clinical assessment with ultrasound in the management of secondary postpartum haemorrhage. European journal of obstetrics, gynecology, and reproductive biology, 2002, Sep-10, Volume: 104, Issue:2 Topics: Anti-Bacterial Agents; Cesarean Section; Cohort Studies; Delivery, Obstetric; Female; Humans; Noreth	2002
Successful treatment of acute promyelocytic leukaemia during pregnancy. Clinical and laboratory haematology, 2002, Volume: 24, Issue:5 Topics: Adolescent; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Cerebral Hemorrhage; Ce	2002
Decreasing bleeding effect of transamin on the induced abortion. Zhonghua fu chan ke za zhi, 2002, Volume: 37, Issue:7 Topics: Abortion, Induced; Female; Humans; Pregnancy; Tranexamic Acid; Uterine Hemorrhage	2002
[Antihemorrhagic prophylaxis in low risk surgery in Bernard-Soulier syndrome]. Revista espanola de anestesiologia y reanimacion, 2005, Volume: 52, Issue:9 Topics: Adult; Antifibrinolytic Agents; Bernard-Soulier Syndrome; Deamino Arginine Vasopressin; Female; Hemo	2005
[Bernard-Soulier syndrome during pregnancy: a case report]. Ginekologia polska, 2005, Volume: 76, Issue:10 Topics: Adult; Antigens, Human Platelet; Bernard-Soulier Syndrome; Deamino Arginine Vasopressin; Female; Hum	2005
Pregnancy in a patient of Glanzmann's thrombasthenia. Indian journal of medical sciences, 2006, Volume: 60, Issue:3 Topics: Adult; Antifibrinolytic Agents; Female; Humans; Patient Readmission; Platelet Transfusion; Postpartu	2006
Bernard-Soulier syndrome in pregnancy. Clinical and laboratory haematology, 2006, Volume: 28, Issue:3 Topics: Adolescent; Adult; Bernard-Soulier Syndrome; Blood Platelets; Consanguinity; Deamino Arginine Vasopr	2006
A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. The British journal of dermatology, 2007, Volume: 156, Issue:5 Topics: Angioedema; Antifibrinolytic Agents; Complement C1 Inhibitor Protein; Female; Humans; Pregnancy; Pre	2007
[Obstetric analgesia for a women with type III hereditary angioneurotic edema]. Revista espanola de anestesiologia y reanimacion, 2007, Volume: 54, Issue:4 Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anesthetics, Local; Angioedema; Antifibrinolytic	2007
Abruptio placentae--treatment with the fibrinolytic inhibitor tranexamic acid. Acta obstetricia et gynecologica Scandinavica, 1980, Volume: 59, Issue:2 Topics: Abruptio Placentae; alpha-Macroglobulins; Antithrombin III; Blood Coagulation Factors; Cesarean Sect	1980
Effects of tranexamic acid on the coagulation and fibrinolytic systems in pregnancy complicated by placental bleeding. Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement, 1982, Volume: 5 Topics: Blood Coagulation; Cyclohexanecarboxylic Acids; Female; Fetus; Fibrinolysis; Humans; Pregnancy; Preg	1982
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2 Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P	1993
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2 Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P	1993
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2 Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P	1993
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2 Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P	1993
Tranexamic acid in the management of postpartum haemorrhage. British journal of obstetrics and gynaecology, 1996, Volume: 103, Issue:12 Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post	1996
Tranexamic acid in the management of postpartum haemorrhage. British journal of obstetrics and gynaecology, 1996, Volume: 103, Issue:12 Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post	1996
Tranexamic acid in the management of postpartum haemorrhage. British journal of obstetrics and gynaecology, 1996, Volume: 103, Issue:12 Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post	1996
Tranexamic acid in the management of postpartum haemorrhage. British journal of obstetrics and gynaecology, 1996, Volume: 103, Issue:12 Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post	1996
[Hereditary angioedema in the German-speaking region]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1998, Volume: 49, Issue:2 Topics: Adolescent; Adult; Angioedema; Child; Child, Preschool; Complement C1 Inactivator Proteins; Danazol;	1998
Hereditary angiooedema. Lancet (London, England), 1979, Mar-17, Volume: 1, Issue:8116 Topics: Adult; Age Factors; Aged; Angioedema; Danazol; Female; Humans; Male; Middle Aged; Pregnancy; Pregnan	1979
Recurrent abruptio placentae treated with the fibrinolytic inhibitor tranexamic acid. British medical journal, 1978, Mar-25, Volume: 1, Issue:6115 Topics: Abruptio Placentae; Cyclohexanecarboxylic Acids; Female; Humans; Pregnancy; Recurrence; Tranexamic A	1978
Inhibition of fibrinolysis and abruptio placentae. British medical journal, 1978, May-13, Volume: 1, Issue:6122 Topics: Abruptio Placentae; Cyclohexanecarboxylic Acids; Female; Fibrinolysis; Humans; Pregnancy; Tranexamic	1978
Inhibition of fibrinolysis and abruptio placentae. British medical journal, 1978, Sep-30, Volume: 2, Issue:6142 Topics: Abruptio Placentae; Cyclohexanecarboxylic Acids; Female; Fetal Death; Humans; Pregnancy; Tranexamic	1978
[Prolonged treatment with tranexamic acid (Cyclocapron) during pregnancy]. Ugeskrift for laeger, 1976, Jul-12, Volume: 138, Issue:29 Topics: Adult; Cyclohexanecarboxylic Acids; Female; Fibrinolysis; Humans; Pregnancy; Pregnancy Complications	1976
On fibrinolysis in reproduction. Acta obstetricia et gynecologica Scandinavica. Supplement, 1975, Volume: 41 Topics: Adolescent; Adult; Aged; Animals; Decidua; Depression, Chemical; Female; Fibrinolysis; Humans; Male;	1975
[Possibilities of the use of an inhibitor of hemolysis (AMCHA), by rectal and vaginal administration, for gynecological hemorrhages]. Minerva ginecologica, 1975, Volume: 27, Issue:4 Topics: Adolescent; Adult; Aged; Blood Coagulation Disorders; Child; Cyclohexanecarboxylic Acids; Female; He	1975
Hereditary angioedema: the clinical syndrome and its management. Annals of internal medicine, 1976, Volume: 84, Issue:5 Topics: Adolescent; Adult; Aged; Aminocaproates; Angioedema; Blood Transfusion; Child; Complement Inactivato	1976
DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thrombosis research, 1987, Jan-15, Volume: 45, Issue:2 Topics: Adolescent; Adult; Aged; Blood Coagulation; Blood Platelet Disorders; Child; Deamino Arginine Vasopr	1987
[Clinical study of nephrotic hematuria of unknown etiology]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1985, Volume: 76, Issue:11 Topics: Adolescent; Adult; Age Factors; Female; Hematuria; Humans; Male; Pregnancy; Prognosis; Tranexamic Ac	1985

Intervention	Participants (Count of Participants)
	Packed red cells	Cryoprecipitates	Fresh frozen plasma	Platelet concentrates
Type 3 Von Willebrand's Disease (VWD3)	24	123	10	1

tranexamic acid and Pregnancy

Research Excerpts

Research

Studies (286)

Authors

Clinical Trials (41)

Trial Overview

Trial Outcomes

Blood Volume Loss

D-Dimer (µg/mL)

Fibrinogen (mg/dL)

Plasminogen Activator Inhibitor-Type-1 (Units/mL)

Rotational Thromboelastometry INTEM and EXTEM Clotting Time

Rotational Thromboelastometry INTEM, EXTEM, FIBTEM Maximum Clot Firmness

Tissue Plasminogen Activator Antigen (ng/mL)

Change in Hemoglobin

Length of Stay

Number of Mothers Who Died or Had Thromboembolic Events (Venous or Arterial), Ischemic Stroke, Myocardial Infarction, New-onset Seizure Activity, or Were Admitted to the Intensive Care Unit for More Than 24 Hours

Number of Participants Who Received Open Label TXA or Other Antifibrinolytic

Number of Participants Who Received Surgical or Radiologic Interventions to Control Bleeding and Related Complications

Number of Participants Who Received Treatments and Interventions in Response to Bleeding and Related Complications

Number of Participants Who Were Transfused With 4 or More Units of Packed Red Blood Cells

Number of Participants Who Were Transfused With Other Blood Products

Number of Participants Who Were Treated With Uterotonics Other Than Oxytocin

Number of Participants With a Thromboembolic Event (Venous or Arterial), Ischemic Stroke, or Myocardial Infarction

Number of Participants With Estimated Blood Loss Greater Than 1 Liter During Delivery

Number of Participants With Maternal Death or Transfusion of Packed Red Blood Cells

Number of Participants With Postpartum Infectious Complications

Number of Participants With Seizure Activity That Was Not Seen Prior to Study Enrollment

Blood Transfusion (Number of Units Transfused) Intraoperatively

Estimated Blood Loss (EBL)

Median Number of Transfused Units of Red Blood Cells (RBC)

Number of Patients Receiving Blood Transfusions

Number of Patients With Clinically or Radiologically Verified Thromboembolic Events Within 5 Weeks Postoperatively

Number of Units of Red Blood Cells (RBC) Transfused

Perioperative Bleeding Volume

Centralized Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Centralized Factor VIII (FVIII) Antigen (FVIII:Ag) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Centralized Factor VIII (FVIII) Procoagulant Activity (FVIII:C) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Centralized Von Willebrand Factor (VWF) Propeptide Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Centralized Von Willebrand Factor Antigen (VWF:Ag) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Local Laboratory Tests for Type 3 Von Willebrand's Disease (VWD3) Diagnosis (Composite)

Number of Patients With Available Local Laboratory Test for Anti-Von Willebrand Factor (Anti-VWF) Antibodies

Patients Experiencing Allergic Reactions During Use of Von Willebrand Factor (VWF)-Containing Concentrates

Number of Participants With Previous Use of Blood Products

Reviews

Trials

Other Studies